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 The treatment of cancer has long relied upon the use of non-specific and toxic 
chemotherapies and radiation that target quickly dividing cells. As a result, many patients 
experience the severe side effects associated with these therapies including vomiting, nausea, 
fatigue, and alopecia. Additionally, these therapies fail to provide durable and lasting responses in 
most cases of metastatic disease.  
The immune system has long been though to play an important role in preventing cancer 
through immune surveillance; the idea that the immune system is poised with the means to detect 
cancer early on and eliminate malignant cells. However, as evident by aggressive disease, cancer 
is able to evade immune recognition and ultimately become very advanced. In recent years, 
immunotherapy has changed the treatment paradigm for several types of cancer. Of note, 
checkpoint blockade inhibitors have provided durable and lasting responses for a minority with 
metastatic disease. While these advances in therapy have provided hope where there was none in 
the cases of aggressive disease, there is still much work to be done to expand the benefits of 
immunotherapy for a small subset of patients to the whole.  
In an effort to understand why certain patients respond to immunotherapy while other do not, 
there has been an effort to collect as much data through a variety of high-throughput ‘big data’ 
assays including whole exome sequencing, single-cell assays, and T-cell receptor sequencing. In 
this doctoral work, we develop a variety of machine learning and artificial intelligence methods to 
parse the nature of this data to unveil concepts that have helped us understand the prerequisites for 
a successful immune response to eliminate cancer. Of note, we develop a collection of deep 
learning algorithms to understand the interaction of peptide-MHC and T-cell receptor that is 
ultimately responsible for successful recognition of tumor by the immune system.  
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The treatment of cancer has long relied upon the use of non-specific and toxic chemotherapies 
and radiation that target quickly dividing cells. As a result, many patients experience the severe 
side effects associated with these therapies including vomiting, nausea, fatigue, and alopecia1. 
Additionally, these therapies fail to provide durable and lasting responses in most cases of 
metastatic disease2.  
In recent years, there has been a significant shift in the way oncologists treat cancer with the 
advent of immunotherapy; the approach of harnessing the host immune system to target and 
eliminate malignant cells. The concept that the immune system could play a key role in prevention 
and progression of cancer first came in 1909 by Ehrlich, who proposed that through a mechanism 
of “surveillance,” the immune system could detect and eliminate cancer.6 Further work in the 2001 
showed that RAG2-deficient mice (lacking T-Cells, B-cells, and NK cells) spontaneously 
developed adenomas of the lung and intestine3. With the advent of monoclonal antibodies, 
Ritixumab (anti-CD20) was one of the first clinically implemented forms of immunotherapy used 
as a first-line therapy for low-grade or follicular CD20-positive non-Hodgkin’s lymphoma.  
In the most recent wave of cancer immunotherapy, checkpoint blockade therapy (α-PD1,α-
CTLA4) has provided the potential to unleash the immune system in novel ways. While PD1 and 
CTLA4, found on CD8+ T-cells and regulatory T-cells, are meant to control an overactive and 
potentially harmful immune response, malignant cells 
can signal through these molecules to suppress the 
immune response as a form of peripheral tolerance 
(Figure 1)4,5. By blocking these signals on T-cells, the 
‘brake’ is removed and they can carry out their 
cytotoxic activity against the tumor.  
Figure 1: Malignant cells are able to induce a form of 
peripheral tolerance by constitutively expressing 
PDL1, which engages PD1 on T-cells (6).  
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The simplicity of checkpoint blockade is that it does not require prior knowledge of the 
antigenic targets of the T-cells it activates. This allows the drug to be broadly applied to various 
types of malignancies quickly without prior sequencing of the patient’s tumor. In essence, it 
assumes that the patient’s immune system is equipped with the means to eliminate the tumor and 
simply needs to be given the right advantage through checkpoint blockade. Unfortunately, while 
responses on checkpoint blockade can be durable and are associated with far fewer side effects 
than traditional chemotherapy, the response rate is relatively low. In the initial α-PD1 trials, across 
non-small-cell lung cancer, melanoma, and renal-cell cancer (considered highly immunogenic), 
the cumulative response rates were 18%, 28%, and 27%, respectively6. Much effort has been 
placed on understanding the immunological reasons for 
successful response to therapy so that response rates can be 
increased. Initial studies demonstrate that the efficacy of 
the checkpoint blockade is highly correlated with 
mutational load (Figure 2), suggesting that the CD8 T cells 
that are being activated against the tumor are neoantigen 
specific; targeting patient-specific passenger mutations 
such as missense mutations that occur due to the 
pathogenesis of the disease7.  
While preliminary studies have elicited some themes that are associated with response to 
immunotherapy, such as total mutational burden (TMB), there still exists a lot of weakly 
understood reasons for why certain patients benefit from therapy while others do not. As a result, 
investigators have developed and applied a variety of technologically advanced techniques such 
as whole-exome sequencing (WES) to understand the genetics of different tumors, immune 
Figure 2: Kaplan-Meier Survival Curve as a 
function of mutational load. Patients with 
higher mutational loads had improved 
response to checkpoint blockade (7).  
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repertoire analysis in the form of T-cell repertoire analysis to query the adaptive immune response 
that is responsible for eradicating tumors, and a host of single-cell techniques including flow 
cytometry, CyTOF, and single-cell RNA sequencing (SC-RNAseq) to describe the phenotypic 
nature of the tumor microenvironment. The resulting tour de force has resulted in very large 
datasets that are highly complex and hold an incredible amount of information. Thus, there exists 
great opportunities in developing algorithms to parse these high-dimensional datasets in order to 
help understand the complex interaction of the immune system with cancer with the potential of 
developing better biomarkers and immunotherapies. 
In the computer science field, there has also been a similar revolution in the fields of artificial 
intelligence (AI) and machine learning (ML). In fact, the greatest use of AI/ML has been for pattern 
recognition in large datasets and the results have been in some cases, better than human 
performance8–10. In this work, we explore a variety of machine learning methods and create tools 
for the field to analyze a variety of data generated from the cancer immunology field including 
WES, TCRSeq, and CYTOF data and demonstrate the power of these methods to provide 
descriptive and predictive insights that ultimately hold promise for improving our understanding 




II. ImmunoMap: A Bioinformatics Tool for T-Cell Repertoire Analysis 
Abstract 
Despite a dramatic increase in T-cell receptor (TCR) sequencing, few approaches biologically 
parse the data in a fashion that both helps yield new information about immune responses and may 
guide immunotherapeutic interventions. To address this issue we developed a method, 
ImmunoMap, that utilizes a sequence analysis approach inspired by phylogenetics to examine TCR 
repertoire relatedness. ImmunoMap analysis of the CD8 T-cell response to self-antigen (Kb-TRP2) 
or to a model foreign-antigen (Kb-SIY) in naïve and tumor-bearing B6 mice showed differences 
in the T-cell repertoire of self- versus foreign antigen-specific responses, potentially reflecting 
immune pressure by the tumor,  and also detected lymphoid organ-specific differences in TCR 
repertoires When ImmunoMap was used to analyze clinical trial data of tumor-infiltrating 
lymphocytes (TILs) from patients being treated with anti–PD-1,  ImmunoMap, but not standard 





The advent of high-throughput immune sequencing has allowed scientists and clinicians to 
understand antigen-specific interactions of the immune response with various pathologies from a 
systems-like perspective. Its initial applications showed the depth and breadth of the T-cell 
receptor (TCR) and B-cell receptor (BCR) repertoire11–14. Further applications of immune deep-
sequencing have contributed to vaccine development and to tracking disease progression in 
malignancies15–17. Sequencing efforts have improved our understanding of immune responses to 
cancer, characterizing the TCR repertoire of circulating as well as tumor-infiltrating lymphocytes 
(TILs)18,19.  
With the abundance of new “big data” sets, a need has arisen to develop biologically meaningful 
techniques for analysis of TCR repertoire sequences. Current analysis methods fall short of 
providing an intuitive understanding of the immune system repertoire for two reasons. First, as 
purely mathematical constructs, they focus on diversity defined as a function of the number of 
different sequences and their respective frequencies, Shannon entropy, and ignore sequence 
relatedness20,21. Second, methods that compare different repertoires apply stringent criteria by only 
comparing exact TCR clonotypes (whether at the nucleotide or amino acid level) to assess 
similarity 19,22,23. 
However, biological sequence similarity, not identity, is the relevant parameter. Ignoring sequence 
relatedness is a significant omission, becauseTCRs with similar, homologous sequences likely 
recognize related MHC/peptide targets. Several groups have sought to understand the structural 
aspects of the underlying TCR repertoire through a variety of techniques that cluster homologous 
CDR3 sequences, showing that, indeed, TCRs that recognize the same antigen have highly 
homologous sequences24–26. Although this work highlights the relevance and rationale behind 
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analyzing TCR sequence repertoire data via clustering methods, we sought to create structural 
diversity metrics for whole TCR repertoires. To address this, we developed ImmunoMap, which 
visualizes and quantifies immune repertoire diversity in a holistic fashion. ImmunoMap not only 
enables assessment of similarity between TCR sequences, but displays the scope of diversity 
among different repertoires. Our approach combines information about the frequency and 
relatedness of TCR sequences by using a sequence analysis inspired by phylogenetics to determine 
relatedness among cells of an antigen-specific T-cell response, as well as the similarities of a 
particular TCR repertoire to other repertoires.  
We initially trained ImmunoMap on the TCRs used by T cells responding to Kb-TRP2, a shared 
self-peptide tumor antigen, and Kb-SIY, a model foreign-antigen, in a model of murine melanoma.  
ImmunoMap analysis showed that in naïve animals, the response to Kb-SIY was highly conserved, 
with many TCR sequences having high sequence homology, a biological observation that we 
missed when using Shannon entropy calculations. In contrast, the bulk of the self-antigen response 
was comprised of fewer and more distantly related sequences. The presence of tumor had a 
differential effect on the shaping of the repertoire in the model foreign and self-antigen responses, 
greatly altering the TCR repertoire of the self-antigen response, with a smaller effect on the 
response to the foreign antigen. To understand the clinical utility of ImmunoMap, we compared 
ImmunoMap to Shannon entropy analysis of TILs from melanoma patients on anti–PD-1 therapy. 
Whereas Shannon entropy calculations did not find any clinically relevant correlates, ImmunoMap 
found clinically relevant, predicative TCR signatures in patients who responded to anti–PD-1 
therapy after just 4 weeks on therapy. Thus ImmunoMap proved more effective in finding a 
clinically useful parameter that another repertoire analysis technique could not. 
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Materials and Methods 
Mice: C57BL/6j mice were purchased from Jackson Laboratories (Bar Harbor, ME). All mice were 
maintained according to Johns Hopkins School of Medicine IACUC 4-5 mice (gender and age 
matched) were used and pooled for each stimulation condition, based on previous T-cell expansion 
experiments, and each stimulation and sequencing run was performed once. Mice were randomly 
selected for naïve or tumor-bearing treatments and principal investigator was blinded to which 
mice received tumors. Murine experiments for naïve and tumor-bearing spleens were duplicated 
in separate pools of animals to demonstrate reproducibility of antigen-specific repertoire 
characteristics (Supplementary Fig. S7).   
Preparation of MHC-Ig dimers and nano-aAPC: Soluble MHC-Ig dimers, Kb-Ig, was prepared 
and loaded with peptides as described 27.. Nano-aAPC were manufactured by direct conjugation 
of MHC-Ig dimer and anti-CD28 antibody (37.51; Biolegend) to MACS Microbeads (Miltenyi 
Biotec) as described previously28.  
Lymphocyte isolation:  Mouse lymphocytes were obtained from homogenized mouse spleens after 
hypotonic lysis of RBC. Cytotoxic lymphocytes were isolated using a CD8 magnetic enrichment 
column from Miltenyi Biotec (Cologne, Germany) following the manufacturer’s instructions. 
Lymphocytes from lymph nodes were obtained from homogenized inguinal lymph nodes and 
enriched with nano-aAPCs and plated for 7 days. For tumor-bearing animals, murine melanoma 
cell line B16-SIY, obtained with the consent of Tom Gajewski (The University of Chicago, IL, 
USA) through Charles Drake in 2011, and re-authenticated in the past year by flow cytometry, was 
injected subcutaneously after 5 days of culture, measured by calipers and harvested when tumors 
reach over 50mm2. The B16-SIY cell line is a tumor model modified to express SIY, a completely 
foreign epitope to the murine B6 background. In naïve mice setting experiments, it was used as a 
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model foreign antigen such as would be a viral epitope and in tumor-bearing animals serves as a 
tumor antigen. Tumor-infiltrating lymphocytes were obtained from tumors by manual digestion 
and washing, a density gradient centrifugation (Lympholyte Cell Separation Media, Mouse, Cedar 
Lane), and then tumor cells plated for 3 hours at 37°C and lymphocytes washed off and plated 
with nano-aAPCs (1.25x109 particles/mL). All cell lines underwent testing for mycoplasma 
contamination. 
Enrichment and expansion: Nano-aAPC were stored at a concentration of 8.3 nM (5 x 1012 
particles/mL), and all volumes refer to particles at this concentration. Ten million CD8+-enriched 
lymphocytes at ~108 cells/mL were incubated with 10 L of nano-aAPC for 1 hr at 4 °C, for an 
approximate bead:cell concentration of 5000:1. Cell-particle mixtures were subsequently passed 
through a magnetic enrichment column, the negative fraction was collected and the positive 
fraction eluted. Positive fractions were mixed and cultured in 96-well round-bottom plates for 7 
days in complete RPMI-1640 medium supplemented L-glutamine, non-essential amino acids, 
vitamin solution, sodium pyruvate, β-mercaptoethanol, 10% FBS, ciproflaxin, and 1% T-cell 
growth factor, a cytokine cocktail derived from stimulated PBMC as described in the literature29, 
in a humidified 5% C02, 37 °C incubator for 1 week. Specificity of CTLs was monitored on day 
7, by FACS analysis following LIVE/DEAD cell stain (Thermo Fisher), anti-CD8 (BD 
Pharmingen, Cat# 553035, 53-6.7), and dimeric MHC-Ig staining. The number of antigen-specific 
cells was calculated by multiplying the number of total T cells by the fraction of CD8+ and antigen-
specific T cells; the fraction of antigen-specific cells was calculated after subtracting the non-
cognate MHC staining from cognate MHC staining. 
Sorting and sequencing of antigen-specific CD8+ T cells: Following LIVE/DEAD cell stain 
(Thermo Fisher), anti-CD8 (BD Bioscience), and dimeric MHC-Ig staining, cells were sorted by 
 9 
gating on cells with cognate Dimeric MHC-Ig staining over non-cognate staining. Antigen-specific 
CD8+ T cells were sent directly for CDR3 β-chain sequencing by Adaptive Biotechnologies.  
In vitro nano-aAPC functionality assay: 7 days following enrichment and expansion antigen 
specificity is confirmed by intercellular cytokine staining. Briefly, RMA-S, given by Michael 
Edidin (Johns Hopkins University, MD, USA) in 1996 (reauthenticated in the past year by peptide 
stabilization assays and cultured for 7 days prior to use) are peptide pulsed (10 M) overnight at 
room temperature with relevant or no peptide and mixed 1:2 RMAS:T-cell ratio with expanded T 
cells. Unpulsed RMAS cells were used as background stimulation. After 6 hours, cells were 
washed twice with FACS wash buffer and then stained with viability dye and anti-CD8 for 20 
minutes. Cells were then fixed and permeabilized with the Cytofix/Cytoperm kit (BD Biosciences) 
following the manufacturer’s protocol. Anti-TNFα (Biolegend, Cat# 506324, MR6-XT22) was 
added to the cells and stained for an hour. 
Precursor frequency assessment: On day 0 following CD8+ T-cell isolation from splenic cells, 
CD8+ T cells were stained with LIVE/DEAD cell stain (Thermo Fisher), anti-CD8 (BD 
Bioscience), and dimeric MHC-Ig staining viability stain with either unloaded or peptide-loaded 
MHC-Ig.  Cells gated on Live cells and anti-CD8a+ staining. 
Collection of TILs from patients undergoing α-PD1 therapy:  
Eighty-five patients, providing written consent, were accrued to a multi-arm, multi-institutional, 
institutional-review-board-approved, prospective study (BMS-038) to investigate the 
pharmacodynamic activity of nivolumab. All patients received nivolumab (3 mg/kg Q2W) until 
progression for a maximum of 2 years. Tumor samples were collected prior to and four weeks after 
initiation of nivolumab therapy. The samples were stored in RNAlater®(Ambion). 34 patients 
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permitted TCR sequencing, and DNA was extracted and submitted to Adaptive Biotechnologies 
for survey level TCR β-chain sequencing 13,30. Clinical response was assessed via CT scan after 
24 weeks of therapy. 
Deconvolution methods: Due to the fact that animals were pooled together on day 0 prior to 
expansion of antigen-specific cells, there was only one sequencing run. In order to determine the 
variance of calculated indicators of the repertoire, the reads from the sequencing file were 
randomly distributed into the number of bins corresponding to the number of animals that went 
into the experiment. This method of random deconvolution assured that the variance of the 
indicator by random chance was not greater than the difference observed between conditions.  
Weighted repertoire dendrograms:  For the antigen-specific sequencing, productive sequences 
with a frequency > 0.01% were taken for analysis. For anti–PD-1 clinical trial analysis, Adaptive 
Biotechnologies’ files were first filtered to only include sequences with reads greater than or equal 
to 5 and then top 40% of response was taken for analysis. Sequence distances were calculated 
based on sequence alignments scores using a PAM10 scoring matrix and gap penalty of 30. 
Distance matrix was used to create a dendrogram using the Bioinformatics toolbox in MATLAB. 
Circles were overlaid at the end of the branches corresponding to the CDR3 sequences with 
diameters proportional to the frequency of the sequence. When using the terminology “weighted 
repertoire dendrogram,” this does not infer that the distance matrix used to create the dendrogram 
is weighted; rather, the dendrogram is visually ‘weighted’ by frequency. 
Dominant motif analysis: Using the cluster function in MATLAB toolbox, dendrogram was 
divided into homologous clusters using a homology threshold obtained from analyzing an 
unexpanded adult CD8+ T cell population from a C57BL/6 animal (Supplementary Fig. S1). 
Clusters whose average sequence distance within cluster <= threshold and met a certain frequency 
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cutoff (3% - Supplementary Fig. S1 were denoted as “Dominant Motifs.” Cluster frequency was 
lowered to 1% for α-PD1 clinical trial analysis but held consistent across all patients due to the 
fact that this was not a single antigen-specific population of cells.  
Singular and novel clone analysis: In order to define singular clones, a matrix was setup to 
calculate the mapped sequence distance of every unique combination of sequences in the 
repertoire. Using standard matrix operations within MATLAB, a singular clone was defined as a 
clone whose frequency was 10x the sum of all other homologous clones. Homologous clones were 
those who had a sequence distance determined from the dominant motif analysis. In order to define 
novel clones, the same approach was used, but the matrix was setup in that it calculated the mapped 
sequence distance of every unique combination of sequences between the two repertoires being 
compared. A novel clone was defined as a clone whose frequency was 10x the sum of all 
homologous clones in the other sample.  
TCR diversity score: This measurement of diversity was calculated in a similar method as the 
singular & novel clone analysis. An initial matrix is created where the mapped sequence distance 
is calculated for every unique combination of sequences in the repertoire. Then the average of the 
unique combination calculations is taken, weighted by reads, and reported as the TCR diversity 
score. Additional details of the algorithm behind this calculation are shown in Supplementary Fig. 
S6.   
Shannonntropy calculations: Calculation of Shannon entropy was completed by the following 
formula where pi represents the frequency of each amino acid sequence and n represents the total 
number of sequences present in the response:  
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Statistical methods:  No specific statistical method was used to determine sample size for the 
stimulation cohorts. Two-tailed t-tests were used as provided by GraphPad Prism 5 software for 
all comparative statistics given we expect normal distributions across all experiments.  
Code availability: In order to use the ImmunoMap algorithms, we have developed a MATLAB-
based Graphical User Interface (GUI) that can be found along with the source code at 
https://github.com/sidhomj/ImmunoMap. Supplementary Fig. S8 demonstrates the use of the GUI. 
Data Availability: TCR β-chain sequencing raw data for the murine experiments is found in 
supplementary materials.  
Results  
Overview of ImmunoMap Algorithms 
Weighted Repertoire Dendrograms: In order to visualize the immune response, we created 
weighted dendrograms; combining information about sequence relatedness with information about 
sequence frequency. We initially applied this analysis to data (from the Adaptive Biotechnologies 
Data Portal31) on the response of tetramer-sorted human CD8+ T cells to cytomegalovirus (CMV; 
Fig. 1A). The distance from the end of the dendrogram branches denotes distance in terms of 
sequence homology; the size of the circles at the ends of the branches denotes frequency of the 
sequence, and color denotes V usage. Sequence distance is determined as a function of global 
alignment scores (Needleman-Wunsch 32, PAM10 scoring matrix 33, Gap Penalty = 30) between 
all unique combination of sequences as follows:  
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𝑆𝑐𝑜𝑟𝑒12 = 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝐴𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑆𝑐𝑜𝑟𝑒 (𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 1, 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 2) 
𝑆𝑐𝑜𝑟𝑒11 = 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝐴𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑆𝑐𝑜𝑟𝑒 (𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 1, 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 1) 
𝑆𝑐𝑜𝑟𝑒22 = 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝐴𝑙𝑖𝑔𝑛𝑚𝑒𝑛𝑡 𝑆𝑐𝑜𝑟𝑒 (𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 2, 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 2) 











Figure 1. Elements of ImmunoMap Algorithm A) Weighted Repertoire Dendogram visualize 
relatedness of sequences within repertoire along with relative frequency of CDR3 amino acid 
sequences. B) Dominant Motif Analysis clusters homologous sequences and selects for clusters 
contributing to significant proportion of the response. 3 Dominant Motifs are shown representing 
highly represented structural motifs in this individual’s CMV response. C) Singular Clone 
Analysis defines sequences that expand significantly over the summation of all other homologous 
sequences D) Novel Clone Analysis is implemented when comparing repertoires from different 
samples and a novel clone is defined as one that expands significantly over the summation of all 




Dominant Motif Analysis: In order to parse the many sequences that are detected in antigen-
specific CTL expansion, we sought to perform hierarchical clustering to determine structural 
motifs that dominated the response. Thresholds for sequence homology and frequency were set by 
analyzing the sequences of the naïve B6 CD8+ repertoire, taken from the Adaptive Biotechnologies 
Data Portal34, Supplementary Fig. S1. We used these thresholds to define homology clusters 
based on sequence distance and then examined clusters that met a predefined frequency threshold 
and termed them “dominant motifs” (Fig. 1B). 
Singular and Novel Structural Clones Analysis: We also defined a “singular structural clone” as 
one that has expanded 10x more than the summation of all other homologous clones in a sample, 
representing a singular solution in “sequence space.” (Fig. 1C). When comparing two separate 
CMV-specific sequencing samples, from different individuals, we defined a “novel structural 
clone” as one that has expanded 10x more than the summation of all homologous clones to it in 
another sequencing sample, representing a newly expanded structural clone (Fig. 1D).  
TCR Diversity Score: To quantify the diversity of the entire TCR repertoire, we created a metric 
to quantify the relatedness of an entire sample; defined as the average mapped sequence distance 
of all unique combinations of sequences in a sample, weighted by number of reads per sequence.   
𝑀𝑎𝑝𝑝𝑒𝑑 𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 =  1 −  
1
1 + [𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒]
 
The TCR Diversity score is bounded between 0 and 1, in which a score of 0 would correspond to 
all TCRs in a response being identical and 1 would correspond to all TCRs being infinitely 
different (full details of algorithms to calculate TCR diversity score in Supplementary Fig. S6).  
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Naïve TCR Repertoires against Model Tumor Antigens  
To understand the clonal diversity of antigen responses, CD8+ T cells from naïve B6 mice were 
pooled and expanded against a model foreign-antigen Kb-SIY, or against a self-tumor antigen, Kb-
TRP2 (180-188), as described27,35. Briefly, CD8+ T cells were enriched and stimulated with 
nanoparticle artificial antigen-presenting cells (aAPCs) containing peptide-MHC-Ig molecules and 
cultured in vitro for 7 days (Fig. 2A).  The resultant CD8+ T-cell cultures were antigen-specific by 
both peptide-MHC-Ig staining and cytokine analysis, confirming their functional specificity 
(Supplementary Fig. S2). Initial precursor frequency was also measured in the endogenous 
repertoire and, even though T cells that recognize either antigen could be expanded from naïve 
animals, Kb-SIY antigen–specific T cells had a higher naïve precursor frequency (Supplementary 
Fig. S2). Antigen-specific populations were sorted and the CDR3 region of the TCR Vβ chain was 
sequenced.   
ImmunoMap analysis of Kb-SIY-specific and Kb-TRP2-specific TCRs (Fig. 2B) visualized unique 
aspects of the polyclonal response for both antigens.  Kb-SIY CD8+ T cells consisted of clones 
with homologous TCR sequences; however, the naïve response to Kb-TRP2 was more clonal in 
nature (more high frequency clones) and used more unrelated sequences, each creating a distinct 
clonal variant for antigen recognition.  
Dominant motif analysis showed that anti-Kb-SIY TCR had fewer, yet richer (more sequences per 
motif), dominant motifs than Kb-TRP2 (Fig. 2C, D). Kb-TRP2 specific T cells had a higher 
percentage of clones representing singular structural T-cell expansions and they took up a larger 
portion of the overall TRP-2 antigen-specific response (Fig. 2D – bottom). Comparing the TCR 
diversity scores, Kb-SIY stimulated a more homologous response, whereas Kb-TRP2 had a more 
diverse response. The response to Kb-SIY had a more conserved V usage, predominantly using 
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V13, whereas the response to Kb-TRP2 exhibited a more diverse use of V segments 
(Supplementary Fig. S3).   
 To demonstrate the advantages of the ImmunoMap analysis over traditional analytic methods, we 
calculated Shannon entropies for Kb-SIY vs Kb-TRP2 responses (Fig. 2E). Shannon entropies 
revealed the diversity of the Kb-SIY response to be higher than that of the Kb-TRP2 response. 
However, because the Shannon entropy is largely determined by the number of sequences that are 
present in the Kb-SIY response and not their relatedness, it missed the fact that although more 
sequences responded to Kb-SIY, they were more convergent than the fewer sequences that 
responded to Kb-TRP2. Thus, the ImmunoMap TCR diversity score and dominant motif analyses 






Figure 2. Naïve Repertoire to Kb-SIY vs Kb-
TRP2 antigens. A) Naïve B6 Animals were 
harvested for CD8 T cells from spleens. CD8 T 
cells underwent Enrichment & Expansion 
protocol via nano-aAPC’s and then were 
cultured ex-vivo for 7 days before undergoing 
flow-sorting for antigen-specific cells and being 
sent for TCR β-chain sequencing. B) Weighted 
Repertoire Dendograms where distance of ends 
of branches denotes sequence distance, size of 
circles denotes frequency of sequence, and color 
of circle denotes specific V beta segment usage. 
C) Demonstration of dominant motif’s detected 
for Kb-SIY (left) and Kb-TRP2 (right). 
Frequency and global sequence alignment is 
shown (Red = Fully Conserved Amino Acids, 
Green = Semi-Conserved Amino Acids, Black = 
Nonconserved Amino Acids). D) Top Row – 
Quantification of Dominant Motif Analysis 
comparing the number of dominant motifs, the 
number of sequences per motif, the contribution 
of the sequences in the dominant motifs to the 
response, and the contribution to the response 
per sequence in a dominant motif. Bottom Row – 
Singular Structural Clone and TCR Diversity 
analysis metrics. (n=5). E) Shannon’s Entropy 
Calculations comparing endogenous Kb-SIY to 
Kb-TRP2 responses. (** : P-value ≤ 0.01, *** : 
P-value ≤ 0.001 using the unpaired two-tailed t-
test, bar represents mean ± s.e.m) 
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Tumor Exerts Differential Expansion Pressure on Antigen-Specific Repertoire 
Although we know that tumors exert pressure on the immune response, it is not clear how this 
alters the repertoire of responding T cells. The ImmunoMap approach can provide insight into the 
biological impact of tumors on T-cell responses and TCR usage by studying TCR repertoire 
changes in the presence of tumor (B16-SIY)36. Visualization of the TCR repertoire by 
ImmunoMap analysis (Fig. 3A) showed differential effects of tumors on the repertoire of pooled 
splenic T cells specific for Kb-SIY or Kb-TRP2. The Kb-SIY CD8+ T cell repertoire was largely 
unaltered in response to tumors. In contrast, as seen by ImmunoMap, the Kb-TRP2 response was 
not only more clonal, but also used TCR sequences that had minimal sequence homology to the 
TCRs seen in the naïve C57BL/6 response.  
Dominant motif analysis showed that the presence of tumors increased the number of dominant 
motifs in the Kb-SIY response (Fig. 3B). In contrast, the presence of tumors decreased the number 
of dominant motifs in the Kb-TRP2 response, suggesting directed immune pressure on the self vs 
foreign antigens in the context of tumor. The dominant Kb-SIY motifs were conserved (Fig. 3C). 
In contrast, no common dominant motifs were shared in the Kb-TRP2 response in tumor-bearing 
animals compared to the naïve response. When examining novel structural clones (Fig. 3D), the 
Kb-TRP2 response in tumor-bearing mice had more structurally novel sequences that, combined, 
were a larger portion of the response as compared to the naïve response. Selective pressure by 
tumors on the immune response was also seen in analyzing the V usage between naïve and tumor-
bearing animals (Fig. 3E). We saw the elimination of the use of V16 in the Kb-TRP2 response, 
and an increased use of V5. In contrast, V usage was conserved in the Kb-SIY response between 
naïve and tumor-bearing animals (Supplementary Fig. S4).  
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Figure 3. Effects of Tumor on TCR Repertoire. A) Overlapped weighted repertoire dendograms 
of tumor-bearing vs naïve antigen-specific splenic CD8 responses. (Red = Tumor-bearing 
repertoire. Blue = Naïve repertoire). B) Dominant Motif analysis for Kb-SIY and Kb-TRP2 
responses before and after exposure to tumor (n=5 mice). C) Maintenance of Dominant Motifs 
between Naïve and Tumor-Bearing Repertoire. D) Novel Structural Clone Analysis (n= 5 mice). 
E) V Beta usage of Kb-SIY and Kb-TRP between Naïve and Tumor-Bearing Repertoire. F) 
Shannon’s Entropy Calculations comparing endogenous vs tumor-bearing responses to Kb-SIY 
and Kb-TRP2. (* : P-value ≤ 0.05, *** : P-value ≤ 0.001 using the unpaired two-tailed t-test, bar 
represents mean ± s.e.m) 
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Additionally, when examining the effect of tumors on Shannon entropy (Fig. 3F), we see that 
although maintenance of entropy in the Kb-SIY response and its decrease in the Kb-TRP2 response 
generally complement the ImmunoMap dominant motif analysis, Shannon entropies are 
uninformative about the conservation, or lack thereof, of TCR sequence structure in response to 
the tumor.  
Lymphoid Organ-Dependent Differences in TCR Repertoires in Tumor-Bearing Mice 
We hypothesized that the influence of tumors on the repertoire may also vary depending upon the 
relationship of the lymphoid organ to the tumor site. This was studied by analyzing antigen-
specific TCR repertoires in the spleen versus draining lymph node (dLN), and TILs in pooled 
tumor-bearing mice lymph nodes and tumors. ImmunoMap analysis revealed that the Kb-SIY 
repertoire selects for effective structural motifs as one probes compartments closer to the tumor 
site. This is seen as the richness of dominant motifs decreases, the response contributed by singular 
clones increases, and the TCR diversity score drops as one moves from the spleen towards the 
tumor (Fig. 4B). Additionally, the structural clones expanded in the spleen, dLN, and TILs are 
generally conserved, as can be visualized by the dendrograms (Fig. 4A) and by tracking dominant 
motifs in the 3 lymphoid compartments (Fig. 4C). In contrast, the opposite trend was seen in the 
Kb-TRP2 response. Additionally, dominant motifs between the spleen and draining lymph node 
were not conserved; we were unable to expand any Kb-TRP2 specific cells from the TILs in 




Figure 4. Effects of Tumor on TCR Repertoire in Various Lymphoid Organs. A) Overlapped 
weighted repertoire dendograms (blue = spleen, green = draining lymph node, red = TILs). B) 
Dominant Motif and TCR Diversity Metrics (Kb-SIY n=4 mice, Kb-TRP2 Spleen n=4 mice, Kb-
TRP2 dLN n=5 mice). C) Maintenance of Dominant Motifs between various lymphoid organs. (* 




Analysis of anti–PD-1 Clinical Trial Data Reveals Indicators of Response 
Recent studies have implicated changes in T-cell responses as important in clinical outcomes to 
checkpoint blockade. We therefore applied ImmunoMap analysis to clinical trial data (BMS-038) 
from patients with metastatic melanoma undergoing anti–PD-1 therapy (nivolumab). For this 
analysis, formalin-fixed, paraffin embedded scrapings were taken from 34 patients, the percentage 
of TILs estimated as per Adaptive protocol (Materials and Methods) and CDR3 regions of Vβ-
chains sequenced before and while on therapy (Fig. 5A). The number of TCRs sequenced in all 
samples analyzed was not significantly different (Supplementary Fig. S5).  
ImmunoMap was used to compare the TCR repertoire before and after 4 weeks of anti–PD-1 
therapy (all ImmunoMap metrics in BMS038Results.xlsx). Weighted repertoire dendrograms (Fig. 
5B) revealed distinct differences between responders and nonresponders. Dominant motif analysis 
(Fig. 5C) showed that patients who had more dominant motifs prior to initiation of therapy had 
more favorable responses to therapy. Additionally, those patients who had a decrease in their TCR 
diversity score (Fig. 5C) on therapy had more favorable outcomes to therapy. In contrast, no 
clinically relevant signature could be found by Shannon entropy calculations (Fig. 5D). Thus 
ImmunoMap analysis was superior in its ability to reveal repertoire characteristics that could 







Figure 5. TCR Repertoire Analysis of 
Patients Undergoing α-PD1 (Nivolumab) 
Therapy. A) Clinical Protocol for sample 
collection and response stratification. Pre-
therapy biopsies were taken from tumor sites 
prior to initiation of therapy. 4 weeks after 
initiation of α-PD1 therapy, on-therapy 
biopsies were taken from same tumor sites. TIL 
extraction was completed sent to Adaptive 
Biotechnologies for CDR3 β-chain sequencing. 
B) Token weighted repertoire dendograms for 
each of the cohorts of responders. C) Dominant 
Motif and TCR Diversity analysis (CR = 3, 
PR=5, SR=11, NR=15).D) Shannon’s Entropy 
Calculations for responses prior and after 
initiation of α-PD1. (* : P-value ≤ 0.05 using 





Here we introduce ImmunoMap, a bioinformatics approach to analyze TCR repertoire sequence 
data, and used it to characterize repertoire changes in responses to model murine tumors and in 
patients undergoing immunotherapy for melanoma. By combining information about sequence 
relatedness and frequency, ImmunoMap allows an intuitive appreciation of TCR repertoire 
characteristics that reconciles the structure and function of the repertoire.  
ImmunoMap analysis comparing foreign (Kb-SIY) and self (Kb-TRP2) antigens showed distinct 
differences in the naïve repertoire to these two different antigens. Although interesting, the 
conclusions of this analysis cannot be expanded to all foreign vs self-antigens. The presence of 
more dominant motifs in the Kb-TRP2 response in combination with greater clonality suggests that 
central and peripheral tolerance mechanisms limited clonal responses, with more distinct clones 
occupying a larger portion of the TRP2-specific repertoire. Self-reactive clones, with TRP2-
specific TCRs would either be removed during central thymic development or tolerized in the 
periphery, explaining the inability to find more numerous TCR sequences per dominant motif37–
39. Because our analysis was conducted on expanded antigen-specific populations, our results 
demonstrate the “expansion potential” of the antigen-specific T-cell repertoire for a model foreign 
and shared tumor antigen in the setting of both naïve and tumor-bearing animals.  It is possible 
that the limited TCR relatedness of TRP2 responses could be due to the lower precursor frequency 
in naïve animals, and the T cells that have the ability to expand do not cluster in the same dominant 
motif due to lower initial cell frequency. The impact of pooling animals prior to expansion and 
sequencing must also be considered.  In this scenario, one could be selecting for “public” clones 
and possibly enriching for these parts of the repertoire over “private” clones, unique to each 
animal. Although individual mice are genetically identical, VDJ recombination occurs as an 
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independent process in each animal and the primary TCR repertoire capable of responding to a 
given antigen could vary between individual animals. Therefore, the effects on shaping of the 
repertoire may be most relevant to “public” or conserved sequences. Finally, the higher TCR 
diversity score of Kb-TRP2 alongside with the higher number of dominant motifs suggests that the 
immune system has to reach further to find solutions to bind the cognate antigen/MHC complex.  
Although prior work on TCR clustering has focused on understanding the structural aspects that 
confer antigen-specificity24,25, the effects of perturbations to the immune system on antigen-
specific responses has not been studied. With ImmunoMap, we studied the changes in repertoire 
in response to tumor. We observed that the effects of tumor on the anti-self-Kb-TRP 2 peptide 
repertoire indicate that tumors exert greater pressure on the self- than on the foreign-antigen. Not 
only did the presence of the tumors correlate with an increase the clonality of the response to self, 
via decreases in the number of dominant motifs and increases in their contribution to the net 
response, but tumor-bearing mice could shift their response to different, presumably suboptimal, 
motifs. Additionally, the differences in repertoire characteristics among various lymphoid organs 
for the two different model antigens indicates that tumors effectively eliminated the expansion of 
certain clones from its microenvironment. The consequences of these findings are relevant to both 
antigen-discovery and targeting for immune therapies related to treating cancer. Due to limitations 
of personalized antigen-specific therapy, targeting shared antigens like MART1, a self-antigen 
specific for melanocytes, has been a mainstay of antigen-specific cancer immunotherapy40–42. This 
approach has typically relied on TCR transgenic models in which a single TCR clone is chosen as 
the source for the antigen-specific receptor43–45. Given our analysis, several problems with this 
approach become apparent: (1) antigen-specific expansion not only generates a diversity of TCR 
sequences but one that spans the entire sequence distance of the naïve repertoire, (2) self-antigen 
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expansion represents a limited repertoire and arsenal against a given epitope due to effects of 
tolerance, and (3) the tumor can exert pressure on the self-antigen–specific immune response in a 
more profound way than in the case of a foreign antigen. Our findings call into question the 
approach of using self or over-expressed antigens as targets for immune therapy and highlight the 
importance of exploring responses to neoantigens, novel MHC-specific epitopes that arise from 
mutations in a patient’s individual malignancy46–50 . 
We also have used ImmunoMap algorithms to understand mechanisms of successful immune 
responses to cancer against 4T1, a murine breast cancer model51. In that model, when analyzing 
TILs from animals treated with anti–CTLA-4, radiation, or the combination of these therapies, 
we found that the TCR structural repertoire before therapy from TILs was highly conserved, 
seemingly targeting a single antigen, whereas after combination therapy, the structural response 
broadened within the TILs and each individual animal developed its own uniquely expanded 
repertoire51.  
Finally, we used ImmunoMap to study TILs from clinical trial specimens to determine if structural 
diversity is an important parameter in determining successful immune responses to cancer 
immunotherapy. Our analysis revealed that patients who had more dominant motifs prior to 
therapy responded more favorably to therapy. Additionally, the change in TCR diversity suggest 
that patients who respond to therapy converge on a solution of successful TCR sequences and thus 
their repertoire is actually less diverse after therapy. In contrast to previous work by Madi et. al 
that demonstrated a structural broadening of the peripheral repertoire to anti–CTLA-4 therapy in 
melanoma patients, but did not correlate this finding with response, we focused our analysis on 
studying changes in the repertoire within the TILs and could determine structural signatures of 
response26. Although our findings are significant, we note the scope of the clinical trial was limited, 
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which impacted the distribution of clinical responses. Nevertheless, taken together, ImmunoMap 
analysis revealed that patients with a broader repertoire prior to therapy have a higher probability 
of expanding effective TCR sequences and converging on them.  
ImmunoMap not only has potential for the clinical monitoring of patients on therapy, through 
predictions of their likelihood to respond, but enables the acquisition of biological insights about 
antigen-specific immune responses that could alter current immune therapies.  
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III. AI-MHC: an-allele integrated deep learning framework for improving Class I & Class II HLA-
binding  
Abstract 
Motivation: The immune system has potential to present a wide variety of peptides to itself as a 
means of surveillance for pathogenic invaders. This means of surveillances allows the immune 
system to detect peptides derives from bacterial, viral, and even oncologic sources. However, given 
the breadth of the epitope repertoire, in order to study immune responses to these epitopes, 
investigators have relied on in-silico prediction algorithms to help narrow down the list of 
candidate epitopes, and current methods still have much in the way of improvement.  
Results: We present Allele-Integrated MHC (AI-MHC), a deep learning architecture with 
improved performance over the current state-of-the-art algorithms in human Class I and Class II 
MHC binding prediction. Our architecture utilizes a convolutional neural network that improves 
prediction accuracy by 1) allowing one neural network to be trained on all peptides for all alleles 
of a given class of MHC molecules by making the allele an input to the net and 2) introducing a 
global max pooling operation with an optimized kernel size that allows the architecture to achieve 
translational invariance in MHC-peptide binding analysis, making it suitable for sequence 
analytics where a frame of interest needs to be learned in a longer, variable length sequence. We 
assess AI-MHC against internal independent test sets and compare against all algorithms in the 
IEDB automated server benchmarks, demonstrating our algorithm achieves state-of-the-art for 
both Class I and Class II prediction. 





The ability for T-cells to recognize various epitopes is of paramount importance to 
mounting a potent immune response and ultimately protecting the host52. The relevance for 
understanding the ‘epitome’ for humans to viruses, bacteria, and even various cancers has been 
vital for advances in vaccine development, understanding how pathogens escape immune 
recognition, and even predicting how cancer patients will respond to immunotherapy53–55. Despite 
how much is known about epitope production including processing by the immunoproteasome, 
transport into the endoplasmic re.ticulum (ER), and binding and presentation via major 
histocompatibility (MHC) molecules, prediction of presented epitopes to the immune system is 
still a difficult task56,57. 
The complexity of the task has led many groups to use advanced methods in machine 
learning and artificial intelligence to learn patterns in known MHC-binding peptides in order to 
recognize these patterns when seen in unknown peptides58,59. Artificial neural networks (ANN’s) 
have been employed by some of the leading algorithms to date to act as feature extractors in order 
to recognize patterns59,60. Artificial neural networks, due to their flexibility in terms of changing 
their capacity, serve as universal function approximators, and therefore can learn patterns difficult 
for humans to pick up on. Building on the principal of using neural networks, groups have recently 
begun to utilize a type of neural network architecture termed convolutional neural networks 
(CNN’s) which were originally developed for the purpose of image classification where features 
in an image can be found in different locations and different orientations. By being translationally 
invariant to features, these networks put together the presence of multiple features in an image in 
order to make a decision as to what object is present in the image8. This concept as applied to 
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sequence analysis has been exploited in analyzing DNA-protein binding domains as well as 
predicting HLA Class I binding61–63. 61–63 
While these most recent advances in neural network architectures have improved the 
accuracy of these algorithms, there are still areas for improvement. As a general shortcoming, most 
neural-network based methods of conducting MHC-binding predictions create several models 
across different alleles and different sequence lengths. The result of this process is that while the 
entire data set of known allele/peptide pairings is large, the data becomes split between models 
where each model can only learn sequence features for a subset of the peptides. However, it is 
known that neural networks, especially deep learning models, show the most increase in 
performance when more data is provided for training. Andreatta et. al demonstrated that using a 
gapped-sequence alignment method, they could feed variable length sequences into a fixed-input 
neural network by providing an additional parameter that specified the length of the original 
sequence (L ≤ 8, L = 9, L = 10, L ≥ 11), showing an improvement in MHC Class I binding 
prediction from being able to leverage more data in one model.  
In order to best leverage the amount of data available for known MHC binding, we 
developed Allele-Integrated MHC (AI-MHC), a unified architecture capable of predicting binding 
for either all Class I or all Class II alleles, regardless of sequence length. By allowing MHC allele 
to be an input into the network and joining this with a global max pooling operation following 
convolutions across the peptide sequence, our architecture is able to leverage the most amount of 




Materials and Methods 
Dataset 
In order to train the Class I network, we pulled linear epitopes from the Immune Epitope Database 
(www.iedb.org) who had Class I restriction in humans with quantitative measurements of ic50 by 
purified MHC competitive radioactive and purified MHC competitive fluorescence assays, 
defining binding as peptide/allele pairings with ic50’s < 500nm. We transform the ic50 values by 
the equation (1) to scale from 0 to 1 where values below 1 nM are set to 1 nM and values above 
50,000 nM are set to 50,000 nM.  




We additionally added another large data set of Class I binding predictions from Kim et. al64. We 
then restricted our training to entries where the full allele was provided (i.e. HLA-A*02:01) and 
then aggregated multiple peptide/allele pairings, taking the median value as a consensus where 
there were multiple peptide/allele pairings. In order to train the Class II network, we used a large 
data set published by Jensen et. al, following the same data preprocessing as described above65.  
For the purpose of comparing against other algorithms, we collected all the benchmarks from the 
IEDB automated server benchmarks for both Class I and Class II and restricted our analysis to 
benchmarks collected from competitive quantitative assays given our network was trained on data 






The conventional neural network architecture as initially conceived for image classification tasks 
generally follows the format of stacking multiple convolutional layers with some type of non-
linear activation and generally a max pooling step66. This approach transforms a photograph that 
is wide and tall with few features (RGB channels) to one that is compressed but with many features. 
The max pooling operations reduce the size of the photograph as it passes through the network but 
still maintain local spatial information. Applying this architecture to biological sequence analysis 
where peptides have variable lengths becomes problematic since neural networks require fixed 
size inputs. In the image classification world, this can be solved by rescaling or padding 
photographs so they all have the same pixel-by-pixel dimensions. Rescaling works well since RGB 
channels are continuous variables where down-sampling or interpolation algorithms can be applied 
but fails to translate to sequence analysis as sequences do not have a continuous numerical 
representation. In order to tackle this problem, Vang et. al. took an approach where they trained 
the network for a fixed size input. However, this approach would prevent training an entire allele’s 
set of peptides together which should significantly improve learning since the features between 9 
and 10mers are most likely highly conserved. In order to be able to train a single model for an 
entire class of HLA molecules, we employed an approach where each peptide zero-padded (right) 
into a 15-mer window for Class I and 40-mer window for Class II. (Figure 1A). This allows the 
network to take in sequences up to 15-mer in length for Class I predictions and up to 40-mer in 




Figure 1: AI-MHC Architecture. A) Zero-padding scheme for handling variable length 
sequences. B) Green window highlights problem with max-pooling in segments as areas of null 
sequence can be directly compared to areas of real sequence. C) AI-MHC is designed to take a 
peptide/allele pair which are transformed with either (1) convolutional layers or (2) trainable 
embedding layers learning vector representations of alleles and (3) amino acids. 1024 10-mer 
convolutions with global max pooling are applied to the sequence resulting in a [1,1024] feature 
map for each sequence. The sequence feature map is then concatenated to the [1,512] allele feature 
map. This long-form vector [1,1536] is then followed by 3 fully-connected layers with 50% 






Since certain amino acids may share similar functional properties with others, we wanted 
to train an embedding that captures properties of each amino acid as the network is trained for 
prediction. In previous work, Vang et. al trained an embedding by using the Word2Vec algorithm 
to vectorize each amino acid based on its contextual use within the epitome. We chose to instead 
train the embedding with the classification task in mind as we believe this should learn the most 
salient embedding for the task at hand and our integrated approach would allow for the most 
amount of data to be leveraged towards training this embedding matrix. 
 In order to analyze this type of input to the network, we chose to use parallel convolutions 
of kernel length of 10-mers, knowing this should be large enough to encompass the 9-mer core 
that represents the length of the interacting peptide with the MHC molecule67.  In comparison to 
other methods of biological sequence comparisons that use sequence alignment algorithms to 
assess conserved motifs, this network learns 1024 10-mer ‘trainable’ motif detectors68. The critical 
piece of the algorithm at this point is how it handles the max pooling step following these 
convolutions. Since our inputs can have variable lengths with zero-padding, if we chose a max-
pooling strategy that divided the sequence into segments, we could be comparing segments in 
some windows where there was no sequence information to windows where there was sequence 
information (Figure 1B). This would be especially problematic with Class II molecules where the 
input length can be highly variable. However, by conducting a global max-pooling operation, one 
is able to detect the relevant binding frame regardless of where it lies within the larger sequence.  
 In order to train one unified architecture to predict binding based on sequence and allele 
input, we required an input to the network to be an allele paired to a given peptide. In order to 
integrate information about the allele into the network, we experimented with two methods: 1) 
applying convolutional layers to the actual protein sequences69 of the MHC alleles to extract 
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structural features of each allele (Figure 1C-1) or 2) training an embedding layer of 512 
dimensions in order to learn properties of each allele (Figure 1C-2). This is particularly 
advantageous because by training on a large dataset of all epitopes for various alleles, the net is 
able to learn features or train an embedding that can understand which alleles share similar 
properties and therefore, may share similar binding characteristics. Following either this 
convolutional feature extraction or embedding, this 512-dimensional vector is then joined with the 
1024-dimensional feature vector for the sequence. In experimenting with both approaches, we 
found no difference in overall performance of the classifier and chose to implement a trainable 
embedding layer, as this was more computationally efficient. At this point, 3 fully connected layers 
(combining features extracted from MHC allele and peptide sequence) are implemented in which 
has final layer has a single output from a sigmoid activation, modeling the nM binding of the given 
MHC allele to peptide sequence pairing. The entire architecture was implemented with Google’s 
TensorFlow™ deep learning library. 
Results 
Neural Network Characterization 
The presented neural network architecture contains two critical features that facilitate the use of 
the largest combined dataset of a given class of MHC for training; 1) translational invariance by 
convolutional layers that utilize a global max-pooling operation and kernel size that encompasses 
the entire possible length of the binding interaction between the peptide and MHC molecule and 
2) integration of MHC allele as paired input with peptide sequence via an embedding layer, thereby 
enabling the entirety of the MHC Class I data to be used ensemble for training as compared to 
stratification by MHC allele. Besides creating larger datasets by combining data from different 
alleles and varying sequence lengths, the architecture developed allows the network to learn the 
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properties of both amino acids and MHC molecules during its training, since each have a trained 
embedding matrix based on the data. In particular, an MHC embedding layer learns features of the 
MHC, allowing the model to learn from a larger dataset and translate knowledge of binding 
between alleles in the same supertype, sharing similar binding properties. To prove these points, 
we conducted two experiments that asses the invariance of the network as well as assess the quality 
of the embedding in its ability to cluster similar amino acids and HLA alleles and translate 
knowledge across alleles in the same supertype.  
 In order to test the invariance of the network, we created a synthetic dataset of 10,000 
peptides of varying lengths between 8-11 amino acids resembling either A0201 binding peptides, 
L at P2, V at P970, or a scrambled sequence containing a L and V at random positions (Figure 2A). 
We provided the network the ability to learn one 10-mer feature, as this is the extent of information 
the network should need to make this classification correctly and were able to show that despite 
the L-V motif being placed in various frames in variable length peptides, our network was able to 
achieve perfect classification accuracy, as would be expected from a detect system that exhibited 




Figure 2: Network Characterization. A) Examples from synthetic dataset meant to mimic A0201 
binding motifs (Leucine at P2, Valine at P9) in various frames within 8-11mer sequences. Red 
amino acids correspond to leucine and valine placed in correct and incorrect frames. B) Receiver 
Operating Characteristic of AI-MHC on synthetic dataset. C) Trained embedding layers were 





After training on MHC Class I and Class II data, we examined the embedding layers for both the 
amino acids and MHC alleles and noted that indeed amino acids with similar biophysical 
properties and MHC alleles in the same supertype (Supplementary Table 1)71 were indeed 
clustered together (Figure 2C), suggesting the network had learned which amino acids and HLA 
molecules share similar binding properties. While there does not exist a formal definition of 
supertypes for Class II molecules, we saw a similar clustering of related Class II molecules as well 
(Figure 2C). In order to assess the benefit of training an integrated model, we trained each of the 
sub-alleles of the HLA-A2 supertype in either individual or a unified model and compared their 
AUC values. We noted significant improvements in performance 10 of the 12 A2 supertype alleles 
(Figure 2D), suggesting the network was able to translate its knowledge about the MHC-A2 
supertype across its sub-alleles.  
Class I Metrics 
We collected a total of 148,540 unique allele/peptide pairing with 
ic50 values from the IEDB (www.iedb.org) and a previously 
published dataset by Kim et.al spanning 86 HLA-A,B,C,E alleles 
(Supplementary Table 2). For the purpose of training, we split 
these data sets into a train set of 95% and split the remaining 5% 
for validation and testing, resulting in a train size of 141,113 
peptides, a validation size of 3,713, and a test size of 3,714. The 
network was trained on the train data while validation data was 
used to determine when to stop training the neural network. In this 
set of peptides, our model achieved an overall AUC of 0.956 on 
Figure 3: ROC for Class I and 
Class II models. 
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our internal independent test set (Figure 3A), generally achieving higher AUC values for where 
there was more data available for a given MHC molecule (Table 1). 
 In order to gauge where our algorithm stood against the current state-of-the-art algorithms, 
we pulled all the ic50 benchmarks from the IEDB (www.tools.iedb.auto_bench/mhci/weekly/) to 
assess the performance of our algorithms against the 11 provided algorithms. Since it is unclear 
whether these are considered independent benchmarks as the IEDB cannot verify that the tested 
allele/peptide pairings have not been seen by the benchmarked algorithms, it is difficult to truly 
compare performance at an algorithmic level. Nonetheless, we removed all records in the 
benchmarks from our training data before assessing the performance of our models. Of the 47 
available benchmarks, AI-MHC performed the best on 9/36 datasets (next highest was NetMHC 
3.4 with 7/36) where we had at least 10 peptide examples for training to a given MHC allele. 




Table 1: AUC Values for Class I Alleles 
  
Algorithm Benchmarks Tested




IEDB Consensus 28 2
NetMHC 3.4 (ANN) 33 7
NetMHC 4.0 (ANN) 3 3
NetMHCcons 30 6
NetMHCpan 2.8 33 4





Table 2: Class I – IEDB Benchmark 
Performance. We collected all benchmark datasets 
from the IEDB for which our algorithm had at least 
10 training examples for the allele tested to assess 
performance against 11 of the available algorithms. 
# of Best Performances refers to the number of 
benchmarks a given algorithm ‘won’.  

























































Class II Metrics 
In order to test whether this type of architecture would also be relevant in predicting Class II 
binding, we collected a total of 134,281 unique allele/peptide pairings with ic50 values from a 
previously published dataset by Jensen et.al spanning 80 alleles (Supplementary Table 4). For 
the purpose of training, we again split this data set the same way as with the Class I training, 
resulting in a train size of 127,566 records, a validation size of 3,357, and a test size of 3,358. 
Training was completed in the same way as described above. In our internal independent data set, 
our model achieved an overall AUC of 0.902 (Figure 3B & Table 3). In comparison to AUC 
values published by Jensen et.al on the same data set, our model outperforms all recorded AUC 
values from the NetMHCIIpan-3.2 (AUC = 0.858 ,0.861, 0.826).  Furthermore, we pulled all ic50 
benchmarks from the IEDB (http://tools.iedb.org/auto_bench/mhcii/weekly/) to assess the 
performance of our algorithm against the 6 provided algorithms. Once again, we benchmarked our 
algorithm by removing entries from our training set that appeared within the IEDB benchmarks. 
Of the 54 available benchmarks, our model performed the best on 18/48 datasets which we had at 
least 10 training examples, the second highest number of best performances to NetMHCIIpan-3.1 
(Table 4).  Full comparison of all algorithms on all benchmarks in Supplemental Table 5. 
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# of Best 
Performances
AI-MHC 48 18
Comblib matrices 18 0




Tepitope (Sturniolo) 29 1
Table 4:  Class II – IEDB Benchmark Performance. We 
collected all benchmark datasets from the IEDB for which our 
algorithm had at least 10 training examples for the allele tested 
to assess performance against 11 of the available algorithms. # 
of Best Per 


























































 In this work, we present an integrated deep learning architecture to predict MHC Class I 
and Class II binding, able to achieve state-of-the-art performance through utilizing innovative 
changes in architecture allowing the network to be trained on effectively larger datasets, which is 
a well-known requirement to better training deep neural networks. This is accomplished through 
training an entire class of MHC alleles in a unified model by learning an embedding layer for the 
allele allowing leveraging of binding information between alleles of the same supertype. 
Furthermore, the architecture becomes flexible to sequence input length by utilizing a global max-
pooling operation across the input peptide sequence following convolutions to achieve 
translational invariance where a frame of interest needs to be learned in the context of a longer, 
variable length peptide sequence.  
 In attempting to assess the performance of our algorithm, we noted the difficulty in making 
equivalent comparisons to other algorithms in the field as there are no clear train/test datasets that 
all algorithms can be benchmarked against in sense that we could determine what data should be 
training versus independent test for any given algorithm. In an attempt to conduct a robust analysis, 
we first created an internal independent test set that was not used for training purposes, as per our 
methods section. Our results for Class I and Class II (AUC – Class I = 0.956 & AUC – Class II = 
0.902) suggest our algorithm is one of the top performing algorithms. However, without the ability 
to train/test other algorithms, it is not possible to directly assess exactly where our algorithm stood. 
For Class I assessment, even when removing all IEDB examples from our training, our algorithm 
still had the highest number of best performances on benchmarks where we had sufficient training 
examples. For Class II, we felt we were able to make a fairer comparison as NetMHCIIpan-3.2 
released a large dataset on which they trained/tested. By using the same data and their reported 
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AUC values, we were confident that our algorithm was truly out-performing what is considered 
the best Class II prediction algorithm by ~4% AUC despite not having more ‘best performances’ 
in the IEDB benchmarks. While our dilemma in assessing performance against other algorithms 
is not a new one, we suggest that there needs to be a method, such as the annual ImageNet 
Challenge, by which algorithms can be compared in a fair way where training/testing datasets are 
equivalent across all algorithms to truly assess the best algorithmic approaches. That being said, 
given the volume of data we collected for MHC class I and II in conjunction with the ability of our 
algorithm to more fully leverage each of the sets of data in total, our approach of isolating an 
internal independent test set still allows for the evaluation of performance across thousands of 
allele/peptides. 
 Finally, we have provided a user-friendly website for use of our algorithms for both Class 
I and Class II predictions with performance metrics provided for each allele. We believe this level 
of transparency in the allele-level performance is important to better inform the user of the 
confidence in any prediction based on the number of peptides tested and the internal AUC achieved 







IV. DeepTCR: a deep learning framework for revealing structural concepts within TCR 
Repertoire 
Abstract 
Deep learning algorithms have been utilized to achieve excellent performance in pattern-
recognition tasks, such as in image and vocal recognition8,66. The ability to learn complex patterns 
in data has tremendous implications in the genomics world, where sequence motifs become learned 
‘features’ that can be used to predict functionality, guiding our understanding of disease and basic 
biology61,63,72,73. T-cell receptor (TCR) sequencing assesses the diversity of the adaptive immune 
system, and while prior conventional biological sequence analysis tools have been insightful, they 
can miss signals in the data due to their rigidity68,74,75. We present DeepTCR, a broad collection of 
unsupervised and supervised deep learning methods able to uncover structure in highly complex 
and large TCR sequencing data. We demonstrate its utility across multiple basic science and 
clinical examples, including learning antigen-specific motifs and understanding immunotherapy-
related shaping of repertoire. We further extract meaningful motifs from the trained network as a 
means of explaining the sequence concepts that have been learned to accomplish a given task. Our 
results show the flexibility and capacity for deep neural networks to handle the complexity of high-
dimensional genomics data for both descriptive and predictive purposes.  
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Next-Generation Sequencing (NGS) has allowed a comprehensive description and 
understanding of the complexity encoded at the genomic level in a wide variety of organisms. The 
applications of NGS have grown rapidly as this technology has become a molecular microscope 
for understanding the genomic basis for the fundamental functions of the cell76. In parallel to this 
explosion of NGS applications, in the machine learning world, deep learning has seen a similar 
expansion of applications as computational resources have grown, large advances in algorithms 
and programming libraries have distributed these capabilities to many scientific communities, and 
in particular, big data has transcended all facets of daily life. As a result of these two technological 
revolutions, there exists many opportunities to apply deep learning in genomics as the data 
generated from NGS is very large and highly complex.  
 T-cell receptor sequencing (TCRSeq) is an application of NGS that has allowed scientists 
across many disciplines to characterize the diversity of the immune system77–79 (Supplementary 
Fig. 9). By selectively amplifying and sequencing the highly diverse CDR3 region of the β-chain 
of T-cells, scientists have been able to study the diverse repertoire the immune system generates 
to probe both foreign and native potential antigens. With this new sequencing technology, there 
has arisen a need to develop analytical tools to parse and draw meaningful concepts from the data. 
In recent work, investigators have applied conventional sequence analytics, where either targeted 
motif searches or sequence alignment algorithms have been applied to begin parsing the structural 
data within TCRSeq68,74,75. However, since many of these approaches were initially conceived to 
analyze longer biological strings for the purpose of identifying evolutionary changes at the DNA 
or protein level, problems can arise when applying them to TCRSeq data in which the strings being 
compared are quite short and the end regions are highly conserved. Finally, while these methods 
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are considered unsupervised machine learning approaches, there has been little in the way of using 
supervised approaches to guide the learning process. 
 We present DeepTCR, a package of both unsupervised and supervised deep learning 
methods for analysis of TCRSeq at both the sequence and sample level in order to learn concepts 
in the data that may be used for both descriptive and predictive purposes. In order to demonstrate 
the utility of these algorithms, we collected three previously published datasets including samples 
sorted by antigen-specificity (Glanville_2017 & Sidhom_2017), and samples taken from cohorts 
of tumor-bearing mice treated with various immunotherapies (Rudqvist_2017)51,68,74 
(Supplementary. Fig. 10,11). 
The first class of algorithms we developed are unsupervised deep learning methods that 
learn the underlying distribution of the sequence data in high-dimensional space for the purpose 
of 1) clustering TCR sequences that likely recognize the same antigen and 2) for the first time 
quantifying similarity between whole repertoires based on their structural composition. We 
implement both a variational autoencoder (VAE) and generative adversarial network (GAN) to 
perform dimensionality reductions and data re-representations at a sequence level, using 
convolutional layers in order to learn motifs that describe the distribution of data. We first 
implemented the VAE as autoencoders have been previously described as a common 
dimensionality reduction/data re-representation technique80,81. When implemented with trainable 
convolutional layers, they can become powerful as a data re-representation technique for images, 
allowing downstream analysis such as clustering of similar images. Our implementation of a 
variational autoencoder starts by taking a TCR sequence that is embedded in a fixed-length vector 
with zero right padding (Fig. 1A). We then use a trainable embedding layer, as described in Sidhom 
et. al, to learn meaning of the amino acids, moving them from a discrete to continuous numerical 
 49 
space73. This is followed by convolutional layers, ultimately reducing the sequence to a latent space 
that is described as a multi-dimensional unit gaussian distribution. The sequence is then 
reconstructed from the latent space through the use of deconvolutional layers and the transposition 
of the trainable embedding layer that was used at the beginning of the network. The network is 
then optimized with a gradient-descent based algorithm minimizing a reconstruction loss and 
variational loss, which acts as a mode of regularization. Since this algorithm is primarily trained 
to minimize the reconstruction loss, the concept of sequence length is learned within the network. 
However, since TCR sequences are variable length sequences that describe a structural part of the 
TCR, they can contain length-independent motifs that are required for antigen-specificity, as has 
been previously demonstrated by Glanville et. al74.  
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Figure 1.  Deep Learning Architectures. (a) The variational autoencoder (VAE) is designed to take as a discrete input the amino acid sequence of 
the TCR sequence with a right zero-padding scheme. A trainable embedding layer is used to transform the sequence from discrete to continuous 
numerical domain. Convolutional and fully connected layers transform the sequence into a latent representation that is parametrized by a multi-
dimensional unit gaussian. Reconstruction of the sequence occurs via fully connected and deconvolutional layers followed by the transposition 
of the same trainable embedding layer used at the beginning of the network. (b) The generative adversarial network (GAN) consists of the 
generator and discriminator, separate networks trained with separate objective functions. The generator samples from a multi-dimensional unit 
gaussian to create a ‘fake’ TCR sequence. The discriminator learns to distinguish ‘real’ from ‘fake’ sequences through one layer of convolutions 
with a global max pooling operation to provide translational invariance to the network. Of note, the generator’s output is the continuous and not 
discrete representation of the TCR sequence. The latent space used for downstream analysis is the penultimate layer of the discriminator, here 
described as having dimensions of [256,1]. (c) The single sequence classifier follows a conventional convolutional neural network architecture 
consisting of one convolutional layer with global max pooling and three fully connected layers to a final classification layer. (d) The whole sample 
classifier utilizes a kernel that scans in a horizontal fashion across all sequences in the file resulting in a sequences-by-features tensor. This is then 
multiplied by the frequency vector for each sequence to derive weighted sequence features. These are then summed across the sequence space 
to compute sample level features that are fed into a classification layer.  
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In order to implement an unsupervised deep learning method that could learn features in a 
length independent fashion, we utilized a GAN architecture (Fig. 1B)82. This model consists of two 
networks, the generator and discriminator that train in an adversarial manner, optimizing separate 
objective functions (Supplementary Fig. 12). The generator attempts to model the distribution of 
sequencing data through a generative process where a latent vector is randomly sampled from a 
multi-dimensional unit gaussian and deconvolutional layers are used to create a TCR sequence. 
The discriminator is a network that is trained to distinguish between sequences from the ‘real’ data 
and sequences from the ‘fake’ generated data. Aside from being used to model biological sequence 
data, our implementation of the GAN differs from previously described architectures as it uses a 
discriminator that has only one convolutional layer with a global max pooling operation to achieve 
translational invariance to relevant motifs as described by Sidhom et. al73. In this manner, this 
network is designed to model the underlying sequence distribution in a length independent manner.  
In order to assess how well these unsupervised methods could learn relevant features of 
TCR sequences, we used a previously published dataset of 2067 sequences for 7 specificities used 
to train GLIPH, a state-of-the-art method for clustering TCR sequences74. We note that both 
unsupervised deep learning methods are able to cluster sequences of the same specificity (Fig. 2A) 
and at the whole sample level can make meaningful comparisons between antigen-specific 
repertoires (Fig 2B). When assessing the specificity of these methods to cluster sequences in 
groups specific to a given antigen, the VAE demonstrates comparable performance to GLIPH 
while only requiring the CDR3 β-chain sequence (Fig 2C), demonstrating that 94.48% of clustered 
TCRs (14% of all sequences clustered) were correctly grouped with other sequences of common 
specificity. Furthermore, both the VAE and GAN maintain a high clustering accuracy while 
clustering more sequences. Finally, to assess the characteristics of the clusters formed at various 
 52 
thresholds, we examined the number of clusters and the variance of the lengths of sequences the 
clusters contained (Fig 2D). While the VAE and GAN comparably cluster sequences of common 
specificity and create the same number of clusters doing so, the GAN clusters sequences of 
different lengths far more than the VAE.   
Figure 2. Unsupervised Learning Examples. (a) Heatmaps of sequence-by-features for 7 tetramer sorted populations of antigen-
specific T-cells taken from Glanville_2017 dataset. (b) Heatmaps of samples-by-features for 7 tetramer sorted populations of 
antigen-specific T-cells taken from Glanville_2017 dataset. (c) Clustering specificity of VAE and GAN across various clustering 
thresholds following hierarchical clustering of sequences by their learned features. (d) Number of clusters vs percent of sequences 
clustered at various clustering thresholds for both VAE and GAN (top). Number of clusters vs length variance of sequences within 
clusters for both VAE and GAN (bottom) (e) Heatmaps of sequences-by-features for antigen-specific sequences taken from sorted 
SIY and TRP2 specific T-cells created by VAE and GAN. (SIY = green, TRP2 = yellow) (f) Heatmaps of samples-by-features for 
antigen-specific samples takes from sorted SIY and TRP2 specific T-cells created by VAE and GAN. (SIY = green, TRP2 = yellow) (g) 
Heatmaps of samples-by-features for the tumor-infiltrating lymphocyte (TIL) samples taken from various immunotherapies 




When applying these two separate approaches on the Sidhom_2017 dataset, we note the 
VAE and GAN are able to comparably cluster antigen-specific sequences as well as antigen-
specific samples (Fig. 2 E & F). However, when clustering sequences from their latent 
representations, we noted that the variances in the length of sequences in a given cluster were much 
smaller from the VAE as opposed to the GAN (Supplementary Fig. 13) as we would expect, since 
the VAE learns length dependent features while the GAN does not. When applying these two types 
of unsupervised approaches to the Rudqvist_2017 dataset, we note that both methods identify that 
the control mice have highly conserved structural profiles, as was described in the initial 
publication (Fig 2G). Our experience using these unsupervised approaches demonstrates they can 
be useful not only to cluster TCR sequences of high homology but also to compare repertoires at 
a wholistic level, allowing a method for the first time to quantify similarity between repertoires 
based on their overall structural composition. 
As noted in these datasets, there are often labels associated to TCRSeq, which can either 
be applied at the sequence or sample level. To accommodate labels at the single sequence level, 
we designed a simple convolutional neural network that learns sequence specific motifs in a length 
independent fashion (Fig 1C) to correctly classify sequences by their labels. The second, and 
arguably the more interesting architecture, is a supervised multi-instance deep learning algorithm 
that is able to learn meaningful concepts that may lie within large samples of many sequences, 
either being obscured by the noise of many irrelevant sequences or are weakly predictive at the 
single sequence level (Fig 1D). This whole sample multi-instance classifier uses convolutional 
kernels that scan the entire file, learning features for each sequence. These features are then 
weighted by the frequency of the sequences. Finally, these features are summed across the 
sequences to give a weighted average of a feature/motif within a sample. We first applied the single 
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sequence classifier to the Glanville_2017 dataset and noted there was a weak predictive signature 
that could differentiate the sequences with better performance for antigens with more TCR 
sequences (Fig 3A). However, when creating samples in-silico that used a given number of unique 
sequences per sample, we found an increase in predictive performance at the whole sample level 
as more sequences were used in each sample, demonstrating the ability of a ‘weak learner’ to 
become more predictive when provided with more evidence in aggregate (Fig 3B). When applied 
to the Sidhom_2017 dataset, we note again that while the sequence level classifier is able to achieve 
reasonable performance, the whole sample classifier does far better as it is able to use an entire 
sample of sequences to make a prediction (Fig 3C). This point is further demonstrated in the 
Rudqvist_2017 dataset as these samples are from tumor-infiltrating lymphocytes (TIL) where 
much of the signal comes from background repertoire, making it difficult for a sequence-level 
classifier to work. However, in the whole sample classifier, we see improved performance with 
particular improvement in the RT and Control groups as they have profound structural signatures 
(Fig 3D). Ultimately, the nature of how the T-cell receptor binds its cognate peptide-MHC makes 
prediction at the single sequence level difficult; however, when multiple instances of a concept are 
present, the whole sample classifier can leverage this data in order to make more accurate 
predictions. Finally, given that usually only the β-chain is sequenced, we acknowledge that this 
presents a considerable limitation in ultimately predicting antigen-specificity as both chains are 
important for recognition. Thus, we would expect improved performance across all described 
algorithms when provided both sequencing data for the α and β chains. 
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While there is inherent value in predictive models as they can be used as biomarkers for 
disease, there has been much effort in improving the ‘explainability’ of deep learning models for 
the purpose of understanding what the network learned. In the context of TCRSeq, being able to 
extract knowledge from the network can inform relevant motifs for antigen-specific recognition. 
Therefore, we established a method by which we could query for differentially used motifs at the 
cohort level from the trained network allowing us to identify relevant cohort-specific motifs (Fig 
3 E & F). By extracting the index along with the value of the feature following its convolution and 
Figure 3. Supervised Learning Examples. (a) Receiver Operating Characteristic (ROC) curve for single-sequence classifier on 
sequences taken from 7 T-cell specificities from Glanville_2017 dataset. (b) All unique sequence from Glanville_2017 dataset 
were allocated randomly without replacement into in-silico samples so no sequences were shared among any samples. Samples 
were created with either 5,10, or 20 sequences/file and whole-sample classifier was used to assess predictive power at the whole 
sample level. (c,d) Receiver Operating Characteristic (ROC) curves for single sequence and whole sample classifier for 
Sidhom_2017 and Rudqvist_2017 datasets. (e,f) Representative motifs learned by whole sample classifier for cohorts that had 
highly predictive structural signatures.  
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global max pooling operation, we can identify where in the sequence a kernel is being maximally 
activated and use this to derive the motif being learned. These supervised methods demonstrate 
how predictive models can also be used to generate descriptive results that can inform our 
understanding of the mechanisms at play.  
NGS has become one of the largest sources of big data in the biological sciences, and deep 
learning is a promising modality for analyzing big data where features need to be learned. In this 
work, we present DeepTCR, a collection of unsupervised and supervised deep learning approaches 
to characterize TCRSeq data for both descriptive and predictive purposes. Our unsupervised 
approaches use newly developed techniques from the deep learning community including the 
variational autoencoder and generative adversarial network to relate and compare repertoires at 
the sequence and sample level. We further develop supervised methods in applications where 
labels can greatly help the learning process, such as when there is buried signal in a large sample 
of sequences. While DeepTCR has been developed for analyzing TCRSeq data, the concepts 
introduced within the designed architectures could translate and be applied to a variety of other 
NGS-based technologies. These types of technologies could yield an entire new area of biomarker 
discovery as well as improving our own understanding of the complex concepts within the 





TCR sequencing files were collected as raw tsv formatted files (Supplementary Fig. 1) from the 
various sources cited within the manuscript. Sequencing files were parsed to take the amino acid 
sequence of the CDR3 after removing unproductive sequences. Clones with different nucleotide 
sequences but the same amino acid sequence were aggregated together under one amino acid 
sequence and their reads were summed to determine their relative abundance. Within the parsing 
code, we additionally specified to ignore sequences that used non-IUPAC letters (*,X,O) and 
removed sequences that were greater than 40 amino acids in length. For the purpose of the 
algorithm, the maximum length can be altered but we chose 40 as we did not expect any real 
sequences to be longer than this length.  
TCRSeq Quantitative Metrics 
Basic TCRSeq analyses were initially done to characterize all samples presented in the manuscript. 
In order to characterize the distribution of sequences by frequency, we computed the clonality for 
all samples and characterized the distribution of sequences by their lengths (Supplementary Fig 
3). The code used to generate these plots and do this analysis is attached in supplementary material. 
Data Transformations 
In order to allow a neural network to train from sequence data, we converted the amino acids to 
numbers between 0-19 representing the 20 possible amino acids. These were then one-hot encoded 
as to provide a categorical and discrete representation of the amino acids in numerical space. This 
process was applied prior to all networks being trained. 
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Training VAE 
In order to train the VAE, following creation of the computational graph as described in the 
manuscript and main figure, we applied an Adam Optimizer (learning rate = 0.001) to minimize a 
reconstruction loss and a variational loss. The reconstruction loss is the cross-entropy loss between 
the reconstructed sequence (S) and the one-hot encoded tensor of the input sequence (L) across the 
ith position in the sequence (1). The variational loss is the Kullback–Leibler (KL) divergence 
between the distributions of the latent variables and a unit gaussian (2).  
𝑅𝐿𝑜𝑠𝑠 =  − ∑ 𝐿𝑖 log(𝑆𝑖)
𝑖
     (1) 
𝑉𝑙𝑜𝑠𝑠 = 𝐷𝐾𝐿(𝑁(µ(𝑋), 𝜎(𝑋)||𝑁(0, 𝐼))     (2) 
The variational loss serves as a regularizer to the network as it prevents overfitting of the network 
and direct memorization of sequence to latent space and allows for meaningful downstream 
clustering of the sequences in their latent representation. The variational autoencoder was trained 
until the reconstruction accuracy over the penultimate 10 iterations was greater than 80%. Features 
for all sequences were then extracted from the latent space and used to create either heatmaps of 
sequences by features or a weighted average of the features by the frequency of the sequence was 
used to construct heatmap of samples by features. 
Training GAN 
In order to train the VAE, following creation of the computational graph as described in the 
manuscript and main figure, we applied an RMSProp Optimizer (learning rate = 0.0002) to 
simultaneously minimize the discriminator (3) and generator (4) loss. The training of a GAN can 
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be thought of an abstraction of the minimax algorithm where these two networks train in an 
adversarial fashion until the networks reach a Nash’s equilibrium.  
𝑑𝑙𝑜𝑠𝑠 =  − 
1
2
𝐸𝑋~𝑝𝑑𝑎𝑡𝑎 log[𝐷(𝑥)] + −
1
2
𝐸𝑍  [log (1 − 𝐷(𝐺(𝑧)))]     (3) 
𝑔𝑙𝑜𝑠𝑠 =  −
1
2
𝐸𝑍 [log 𝐷(𝐺(𝑧))]     (4) 
Since this was the first example we could find of a GAN being used in biological sequence 
analysis, there were several modifications to the traditional GAN architecture used for image 
analysis to allow our network to train in a meaningful fashion. The first of these modifications was 
the input into the discriminator. When a generator is conventionally trained, it outputs an image 
with a given x by y dimensionality with 3 RGB dimensions that are continuous. However, in our 
applications, biological sequences are represented in a discrete space and this presented hurdles in 
getting the generator to create discrete representations. Therefore, the network was trained to 
output continuous sequence representations that were already embedded in a continuous domain. 
In a sense, the generator inputs its data in the middle of the discriminator, after the real data has 
already been embedded in a trainable embedding layer. The second point of alteration to the 
traditional GAN comes from the need for the discriminator to be a dimensionality reduction 
operation as oppose to the generator creating real sequences. In order to learn length invariant 
features, our discriminator has only one convolutional layer where the kernel is global max pooled 
across the length of the sequence. This operation creates our latent representation which is 
immediately fed into the final neuron for classification. The nature of this operation results in the 
generator creating sequences which are a conglomeration of motifs found in the original data as 
there is no feedback to the generator about length of the sequences in the original distribution of 
data. Finally, given the simplicity of the discriminator, we found the network was highly 
 60 
susceptible to mode collapse, a type of failure where the generator outputs only sequence because 
it successfully fools the discriminator every time. In order to enforce a wide variety of generated 
motifs and sequences, we applied a feature matching algorithm where we add an additional loss to 




∑‖µ(𝐹(𝑥)) − µ(𝐹(𝐺(𝑧)))‖     (5) 
This loss is the absolute difference between the average feature values for a batch of real 
data and fake data. This loss acts as a regularizer to encourage the generator to create diverse 
batches of sequences, capturing the entire distribution of the data. While this technique worked 
fairly well, we found the network could occasionally still suffer from mode collapse and further 
work is needed in the area of using GAN’s for short sequences.  
Finally, the network was trained in alternating fashion between the generator optimizer and 
discriminator optimizer over each iteration of the network. Training was halted when the average 
discriminator loss over the penultimate 10 iterations fell below 1.0 and the generator loss did not 
fall at least 1% in the penultimate 30 iterations (Supplementary Fig 4). We noted this type of early 
stopping criterion resulted in the generator initially fooling the discriminator quite easily until the 
discriminator learned the appropriate features to distinguish real from fake data. At this point, the 
generator loss would grow and eventually be unable to create sequences capable of fooling the 
discriminator and the training process was stopped at this point.  
Training Single Sequence Classifier 
In order to train the single sequence classifier, we followed a traditional conventional neural 
network architecture where a single translationally invariant convolutional layer was applied to 
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the sequence followed by three fully connected layers to a final classification layer. The network 
was trained using an Adam Optimizer (learning rate = 0.001) to minimize the cross-entropy loss 
between the softmaxed logits and the one-hot encoded representation of the discrete categorical 
outputs of the network. Training was conducted by using 75% of the data for the training set, and 
25% for validation and testing. The validation group of sequences was used to implement an early 
stopping algorithm. 
Training Whole Sample Classifier 
Designing an architecture for whole sample multi-instance classification presented unique 
challenges that were specific to the way TCRSeq data is generated. Not only are the length of 
individual sequences variable length but the length of the individual files can vary in length as well 
in terms of number of unique sequences. Since neural networks required fixed-size inputs, this 
required not only a padding scheme for the sequences but also a padding scheme for the files. 
When a given dataset was imported, we applied a right zero padding scheme to each of the 
sequences but then we padded all zero sequences until every file had the same number of 
sequences. When this tensor is fed into the network, convolutional layers with dimensionality of 
[1, kernel] are then used to scan across the entire file of sequences. This results in feature values 
for each sequence in file. Additionally, since TCRSeq is a count-based NGS technology, there are 
quantitative measurements for each sequence that can be represented as a frequency of the entire 
file. This frequency is then used to weight the features. At this point, the network takes a sum of 
the features across all the sequences for a given file, computing a weighted average of all learned 
features over the entire sample. This vector of weighted average features is then fed directly into 
the classification layer. The network is trained with an Adam Optimizer (learning rate = 0.001) to 
minimize the cross-entropy loss between the softmaxed logits and the one-hot encoded 
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representation of the discrete categorical outputs of the network. Training splits and early stopping 
algorithms are the same as described above for the single sequence classifier except for in the cases 
of the Sidhom_2017 and Rudqvist_2017 datasets as the number of samples (7 & 20) were too small 
to create proper sized train/validation/test sets. Therefore, we used a leave-one-out training 
strategy where we trained on all but one sample until the training loss plateaued and then predicted 
on the one-out. Due to the generally small nature of these cohorts, in either traditional 
train/valid/test or leave-one-out splits, we employed monte carlo cross-validation, randomly 
selecting samples for train/test and iterating a number of times to approximate the predictive 
signature in the dataset. 
Motif Identification 
Neural networks are often treated as ‘black boxes’ where their value is largely in their predictive 
performance and not in understanding how the neural network is accomplishing its task. However, 
in the area of the biological sciences, there is not only the desire to create predictive tools but use 
these tools to inform our own understanding of the mechanisms at play. This area of research is 
often termed as improving the ‘explainability of neural networks. In biological sequence analytics 
such as DeepTCR, investigators want to be able to extract the features/motifs the neural network 
learned to accomplish its task. For the supervised learning architectures, we were able to identify 
motifs the network had learned by extracting the indices of where the kernels were activated 
following the global max pooling layer. The result of this operation is the network not only extracts 
the maximum value of a kernel over the length of the sequence but also deduces its position within 
the sequence. This can be then used to not only pick up which features are activated on a given 
sequence but where in the sequence this activation occurs, allowing us to identify the motifs that 
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any given neuron in the net is learning. Sequence logos were created with 
https://weblogo.berkeley.edu/logo.cgi.  
Code and Data availability 
DeepTCR was written using Google’s TensorFlowTM deep learning library and is available as a 
python package. Source code, comprehensive documentation, and use-case tutorials along with all 
data used in this manuscript can be found at https://github.com/sidhomj/DeepTCR. DeepTCR can 
either be installed directly from Github or from PyPI at https://pypi.org/project/DeepTCR/. 
Acknowledgements 
The authors thank the MARC/SU2C Foundation for providing financial support for the work of 
developing algorithmic pipelines presented in this manuscript. We also would like to thank James 
R. White for editorial assistance and reviewing the DeepTCR codebase.  
  
 64 
V. ExCYT: A Graphical User Interface for Streamlining Analysis of High-Dimensional 
Cytometry Data 
Abstract 
With the advent of flow cytometers capable of measuring an increasing number of parameters, 
scientists continue to develop larger panels to phenotypically explore characteristics of their 
cellular samples. However, these technological advancements yield high-dimensional data sets 
that have become increasingly difficult to analyze objectively within traditional manual-based 
gating programs. In order to better analyze and present data, scientists partner with 
bioinformaticians with expertise in analyzing high-dimensional data to parse their flow cytometry 
data. While these methods have been shown to be highly valuable in studying flow cytometry, they 
have yet to be incorporated in a straightforward and easy-to-use package for scientists who lack 
computational or programming expertise. To address this need, we have developed ExCYT, a 
MATLAB-based Graphical User Interface (GUI) that streamlines the analysis of high-dimensional 
flow cytometry data by implementing commonly employed analytical techniques for high-
dimensional data including dimensionality reduction by t-SNE, a variety of automated and manual 
clustering methods, heatmaps, and novel high-dimensional flow plots. Additionally, ExCYT 
provides traditional gating options of select populations of interest for further t-SNE and clustering 
analysis as well as the ability to apply gates directly on t-SNE plots. The software provides the 
additional advantage of working with either compensated or uncompensated FCS files. In the event 
that post-acquisition compensation is required, the user can choose to provide the program a 
directory of single stains and an unstained sample. The program detects positive events in all 
channels and uses this select data to more objectively calculate the compensation matrix. In 
summary, ExCYT provides a comprehensive analysis pipeline to take flow cytometry data in the 
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form of FCS files and allow any individual, regardless of computational training, to use the latest 




Advances in flow cytometry as well as the advent of mass cytometry has allowed clinicians 
and scientists to rapidly identify and phenotypically characterize biologically and clinically 
interesting samples with new levels of resolution, creating large high-dimensional data sets that 
are information rich83–85. While conventional methods for analyzing flow cytometry data such as 
manual gating have been more straightforward for experiments where there are few markers and 
those markers have visually discernable populations, this approach can fail to generate 
reproducible results when analyzing higher-dimensional data sets or those with markers staining 
on a spectrum. For example, in a multi-institutional study, where intra-cellular staining (ICS) 
assays were being performed to assess the reproducibility of quantitating antigen-specific T cell 
responses, despite good inter-laboratory precision, analysis, particularly gating, introduced a 
significant source of variability86. Furthermore, the process of manually gating population of 
interests, besides being highly subjective is highly time consuming and labor intensive. However, 
the problem of analyzing high-dimensional data sets in a robust, efficient, and timely manner is 
not one new to the research sciences. Gene expression studies often generate extremely high-
dimensional data sets (often on the order of hundreds of genes) where manual forms of analysis 
would be simply infeasible. In order to tackle the analysis of these data sets, there has been much 
work in developing bioinformatic tools to parse gene expression data87. These algorithmic 
approaches have just been recently adopted in the analysis of cytometry data as the number of 
parameters has increased and have proven to be invaluable in the analysis of these high 
dimensional data sets88,89.  
Despite the generation and application of a variety of algorithms and software packages 
that allow scientists to apply these high-dimensional bioinformatic approaches to their flow 
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cytometry data, these analytical techniques still remain largely unused. While there may be a 
variety of factors that have limited the widespread adoption of these approaches to cytometry 
data90, the major hindrance we suspect in use of these approaches by scientists, is a lack of 
computational knowledge. In fact, many of these software packages (i.e., flowCore, flowMeans, 
and OpenCyto) are written to be implemented in programming languages such as R that still 
require substantive programming knowledge. Software packages such as FlowJo have found favor 
among scientists due to simplicity of use and ‘plug-n-play’ nature, as well as compatibility with 
the PC operating system. In order to provide the variety of accepted and valuable analytical 
techniques to the scientist unfamiliar programming, we have developed ExCYT, a graphical-user 
interface (GUI) that can be easily installed on a PC/Mac that pulls many of the latest techniques 
including dimensionality reduction for intuitive visualization, a variety of clustering methods cited 
in the literature, along with novel features to explore the output of these clustering algorithms with 
heatmaps and novel high-dimensional flow/box plots.  
ExCYT is a graphical user interface built in MATLAB and therefore can either be run 
within MATLAB directly or an installer is provided that can be used to install the software on any 
PC/Mac. The software is included with this manuscript. We present a detailed protocol for how to 
import data, pre-process it, conduct t-SNE dimensionality reduction, cluster data, sort & filter 
clusters based on user preferences, and display information about the clusters of interest via 
heatmaps and novel high-dimensional flow/box plots (Figure 1). Axes in t-SNE plots are arbitrary 
and in arbitrary units and as such as not always shown in the figures for simplicity of the user 
interface. The coloring of data points in the “t-SNE Heatmaps” is from blue to yellow based on 
the signal of the indicated marker. In clustering solutions, the color of the data point is based 
arbitrary on cluster number. All parts of the workflow can be carried out in the single panel GUI 
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(Figure 2 & Table 1). Finally, we will demonstrate the use of ExCYT on previously published 
data exploring the immune landscape of renal cell carcinoma in the literature, also analyzed with 
similar methods. The sample dataset we used to create the figures in this manuscript along with 
the protocol below can be found at https://premium.cytobank.org/cytobank/projects/875, upon 




Figure 1: ExCYT Pipeline & Features. (A) ExCYT begins by importing raw FCS data, applying 
optional compensation, gating, and random subsampling prior to downstream analysis. This 
ensures all events being analyzed are relevant to the experiment being analyzed. t-SNE 
dimensionality reduction is then performed to visualize all events and t-SNE heatmaps can be 
generated to visualize phenotypic distributions. Finally, a variety of clustering algorithms can be 
applied on either t-SNE transformation or high-dimensional raw data. (B) Novel sorting and 
thresholding features allow users to quickly sort through possibly hundreds of clusters to find ones 
of interest. (C) Heatmaps of clusters can be created to examine how multiple clusters compare to 
each other as well as which markers co-associate. (D) Novel high-dimensional flow/box plots can 
be generated as a form of back-gating clusters on original data while appreciating the high-




Figure 2: ExCYT Graphical User Interface: The ExCYT graphical user interface allows for a 
streamline work flow working from the left to right of the panel as the user imports their data, 




Table 1. Overview of All Functions Present in the ExCYT GUI 
  
No. Description Name (in GUI)
1 Select type of Cytometry NA
2 Random subsampling of raw data NA
3 Select files for analysis Select File(s)
4 Auto-compensation of raw data based on directory of single stains provided to software Auto-Compensation
5 Gating to select events for t-SNE and clustering analysis Gate Population
6 Random subsampling of gated data (absolute number) NA
7 Random subsampling of gated data (percent of gated population) NA
8 Select channels for analysis NA
9 Run t-SNE dimensionality reduction t-SNE
10 t-SNE Window NA
11 Save workspace Save Workspace
12 Load Workspace Load Workspace
13 Create t-SNE heatmap on select marker NA
14 Gate t-SNE to re-do t-SNE analysis of select population Gate t-SNE
15 Save t-SNE window as image Save TSNE Image
16 Select Clustering Algorithm Clustering Method
17 Enter Clustering Parameter for given algorithm NA
18 Cluster Analysis Cluster
19 Draw Clusters Manually Select Cluster Manually
20 Clear All Clusters to redo cluster analysis Clear Clusters
21 Show Clusters under current filter conditions Clusters (Filtration)
22 Remove select clusters from Cluster Analyze listbox Remove <--
23 Add cluster to Cluster Analyze listbox Select -->
24 Create conventional heatmap of all events in analysis HeatMap of Events
25 Sort clusters by select marker Sort
26 Set threshold by select marker Threshold
27 Create conventional heatmap of select clusters from Cluster Analyze listbox HeatMap of Clusters
28 Flip order of sort Ascending/Descending
29 Clear all thresholds Clear All Thresholds
30 Set frequency threshold for clusters Cluster Frequency Threshold (%)
31 List of current thresholds active on 'Clusters (Filtration)' listbox Thresholds
32 High Dimensional Box Plot High Dimensional Box Plot
33 High Dimensional Flow Plot High Dimensional Flow Plot
34 Horizontal axis parameter for conventional flow plot NA
35 Vertical axis parameter for conventional flow plot NA
36 Data transformation for conventional flow plot on horizontal axis NA
37 Data transformation for conventional flow plot on vertical axis NA
38 Create conventional flow plot Conventional Flow Plot
39 Show Clusters for Analysis NA
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Protocol 
1. Collecting and Preparing Cytometry Data 
1.1. Place all single stains in a folder by themselves and label by the channel name (by 
fluorophore, not marker).  
2. Data Importation & Pre-Processing 
2.1. To pause or save throughout this analysis pipeline, use the Save Workspace button at the 
bottom left of the program to save the workspace as a ‘.MAT’ file that can later be loaded via the 
Load Workspace button. Do not run more than one instance of the program at a time. Therefore, 
when loading a new workspace, make sure to check there is no other instance of ExCYT running. 
2.2. To begin analysis pipeline, first select type of cytometry (Flow Cytometry or Mass 
Cytometry – CYTOF), under the File Selection Parameters, and 2000 events  to sample from the 
file. Once data has been successfully imported, a dialogue box will pop up informing the user that 
the data has been successfully imported.  
2.3. Press the Auto-Compensation button to conduct an optional auto-compensation step, as 
done by Bagwell & Adams91. Select the directory containing single stains. Select the unstained 
sample within the user interface dialogue.  
2.3.1. Place a forward/side-scatter gate on any of the samples in this directory that will be used 
to select events to calculate the compensation matrix. It is recommended to use the unstained 
sample for this purpose. At this point, an algorithm has been implemented to set consistent 
thresholds at the 99th percentile of the unstained sample to define positive events in each of the 
single stains to calculate the compensation matrix. When this is finished, a dialogue box will 
inform the user that the compensation has been performed.  
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2.4. Next, press Gate Population and select the populations of cells of interest, as is the 
convention in flow cytometry analyses. When population of cells is selected, enter 10,000 events 
or % of File to use for downstream analysis.  
2.5. Next, select the channels to be used for analysis in the listbox in the far right of the Pre-
Processing box.  
3. t-SNE Analysis  
3.1. Press the t-SNE button to have the program begin start to compute the reduced 
dimensionality data set for visualization in the window below the t-SNE button. To save image of 
t-SNE, press Save TSNE Image. On a machine with 8 CPU @ 3.4 GHz each and 8 GM RAM this 
step should take about 2 minutes for 10,000 events, 10 minutes for 50,000 events, and 20 minutes 
for 100,000 events.  
3.2. To create a ‘t-SNE heatmap’, as seen in several CYTOF publications92,93, select an option 
from the Marker-Specific t-SNE pop-up menu such as CD64 or CD3. A figure will pop up 
showing a heatmap representation of the t-SNE plot that can be saved for figure generation.  
3.3. Select areas of interest in the t-SNE plots by the user for further downstream analyses using 
the Gate t-SNE button.  
4. Cluster Analysis 
4.1. To begin clustering analysis, select option in Clustering Method listbox such as DBSCAN 
with a distance factor of 5 in dialogue box to the right of the listbox. Press the Cluster button.  
4.2. Use one of the following options for automated clustering algorithms found in the 
‘Automated Clustering Parameters’ panel: 
4.2.1. Hard KMEANS (on t-SNE): Apply k-means clustering to the reduced 2-dimensional t-SNE 
data and requires the number of clusters to be provided to the algorithm94.  
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4.2.2. Hard KMEANS (on HD Data): Apply k-means clustering to the original high-dimensional 
data that was given to the t-SNE algorithm. Once again, the number of clusters needs to be 
provided to the algorithm.  
4.2.3. DBSCAN: Apply the clustering method of clustering, called Density-Based Spatial 
Clustering of Applications with Noise95 that clusters the reduced 2-dimensional t-SNE data and 
requires a non-dimensional distance factor that determines the general size of the clusters. This 
type of clustering algorithm is well suited to cluster the t-SNE reduction as it is able to cluster non-
spheroidal cluster that are often present in the reduced t-SNE representation. Additionally, due to 
the fact that it operates on the 2-dimensional data, it is one of the faster clustering algorithms.  
4.2.4. Hierarchical Clustering: Apply the conventional hierarchical clustering method to the 
high-dimensional data where the entire Euclidean distance matrix is calculated between all events 
before providing the algorithm a distance factor that sets the size of the cluster.  
 
4.2.5. Network Graph-Based: Apply a clustering method that has been most recently introduced 
into analyzing flow cytometry data when there are rare subpopulations that the user wants to 
detect93,96. This method relies on first creating a graph that determines the connections between all 
events in the data. This step consists of providing an initial parameter to create the graph, which is 
the number of k-nearest neighbors. This parameter generally governs the size of the clusters. At 
this point, another dialogue box pops up asking the user to employ one of 5 clustering algorithms 
that is applied to the graph. These include 3 options to maximize the modularity of the graph, the 
Danon Method, and a spectral clustering algorithm96–100. If one wants a generally faster clustering 
solution, we recommend Spectral Clustering or the Fast Greedy Modularity Maximization. While 
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the Modularity Maximization methods along with the Danon method determine the optimal 
number of clusters, Spectral Clustering requires the number of clusters to be given to the program.  
4.2.6. Self-Organized Map: Employ an artificial neural network to cluster the high-dimensional 
data.  
4.2.7. GMM – Expectation Maximization: Create a Gaussian Mixture Model using Expectation 
Maximization (EM) technique to cluster the high-dimensional data101. This type of clustering 
method also requires the user to input the number of clusters.  
4.2.8. Variational Bayesian Inference for GMM: Create a Gaussian Mixture Model but unlike 
EM, it can automatically determine the number of the mixture components k102. While the program 
does require a number of clusters to be given (larger than the expected number of clusters), the 
algorithm will determine the optimal number on its own.  
 
4.3. To study a particular area of the t-SNE plot, press the Select Cluster Manually button to 
draw a set of user-defined clusters. Of note, clusters cannot share members (i.e., each event can 
only belong to 1 cluster).  
5. Cluster Filtration 
5.1. Set(s) of clusters identified either manually or via one of the automatic methods described 
above can be filter via as follows.  
5.1.1. To sort clusters (in the Cluster Filter panel) by any of the markers measured in the 
experiment, select an option from the Sort pop-up menu. To set whether the order is ascending or 
descending, press the Ascending/Descending button to the right of the Sort pop-up menu. This 
will update the list of Clusters in the ‘Clusters (Filtration)’ listbox and re-order them in descending 
 76 
order of median cluster expression of that marker. The percentage denoted in the ‘Clusters 
(Filtration)’ listbox denotes the percent of the population that this cluster represents. 
5.1.2. To set a minimum threshold value for a given cluster across a certain channel, select an 
option from the Threshold pop-up menu such as CD65 and set a threshold at around 0.75.  Either 
type a value in the numerical box below the graph or use the slide-bar to set a threshold. Once 
threshold is set, press Add Above Threshold or Add Below Threshold to specify the direction 
of threshold. Once this threshold has been set, it will be listed in the Thresholds box next to the 
‘Cluster Filter’ panel where the marker, the threshold value, and the direction will be listed so the 
user is aware of which thresholds are currently being applied. Finally, the t-SNE plot will update 
by blurring out clusters that do not meet the requirements of the filtration and the ‘Clusters 
(Filtration)’ listbox will update to show clusters that meet the filtration requirements.  
5.1.3. To set a minimum threshold for frequency of a cluster, enter a numerical cut-off in the 
Cluster Frequency Threshold (%) box in the Cluster Filter panel such as 1%.  
6. Cluster Analysis & Visualization 
6.1. To select clusters for further analysis and visualization, select clusters In Clusters 
(Filtration) listbox and press the Select → button to move them to the Cluster Analyze listbox.  
6.2. To create heatmaps of clusters, select the clusters of interest in the Cluster Analyze listbox 
and press the HeatMap of Clusters button. When this button is pressed, a figure will pop up 
containing a heat map along with dendrograms on the cluster and parameter axes. The dendrogram 
on the vertical axis will group clusters by those that are closely related while the dendrogram on 
the horizontal axis will group markers that are co-associated. To save heatmap, press File | Export 
Setup | Export. 
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6.3. To create a ‘High Dimensional Box Plot’ or ‘High Dimensional Flow Plot,’ select the 
clusters of interest in the Cluster Analyze listbox and press either the High Dimensional Box 
Plot button or the High Dimensional Flow Plot button. These plots can be used to visually assess 
the distribution of given channels of various clusters across all dimensions. 
6.4. To show clusters in traditional 2D flow plots, select the transformation (linear, log10, 
arcsinh) and channel in the Conventional Flow Plot panel and press Conventional Flow Plot.  
 
Representative Results 
In order to test the usability of ExCYT, we analyzed a curated data set published by 
Chevrier et al. titled ‘An Immune Atlas of Clear Cell Renal Carcinoma’ where the group conducted 
CyTOF analysis with an extensive immune panel on tumor samples taken from 73 patients93. Two 
separate panels, a myeloid and lymphoid panel, were used to phenotypically characterize the tumor 
microenvironment. The objective of our study was to recapitulate the results of their t-SNE and 
cluster analysis, showing that ExCYT could be used to come to the same conclusions as well as 
show additional methods of visualization and cluster analysis.  
In the original manuscript, the group described 22 T cell clusters identified by the lymphoid 
panel and 17 cell clusters identified by the myeloid panel. In Figures 3 & 4 of the publication, the 
group shows heatmaps of clusters, t-SNE plots with color-coded clustering solutions, and t-SNE 
heatmaps in subpanels A, B, & C. In order to perform the analysis, we obtained the manually gated 
data from Cytobank and sampled 2000 events from each file or took the entire file if it had less 
than 2000 events, following the analysis pipeline illustrated in the original manuscript. At this 
point, we sampled a total of 100,000 events via our post-gating subsampling parameter, conducted 
t-SNE analysis, and used a variety of clustering methods to explore the data in various ways.  
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First, we examined the myeloid panel by following the same analysis pipeline as the 
original manuscript by completing the t-SNE analysis and creating heatmaps of the various 
markers (Figure 3A). While the original manuscript normalized the t-SNE heatmaps to the 99th 
percentile of each marker, ExCYT does not do this type of normalization for its heatmaps. 
However, similar distributions of marker co-expression were observed as described in the original 
manuscript. We then applied a Network Graph-Based method of clustering the data by creating 
the graph with 100 k-nearest neighbors and clustering the graph via optimizing the modularity of 
the graph by using the Fast-Greedy implementation within ExCYT, where we found 19 sub-
populations of cells (Figure 3B). When comparing the heatmap of these clusters created by 
ExCYT with the heatmap published in the original manuscript, we noted that we were able to 
identify similar clusters of myeloid cells (Figure 3C). Of note, the original manuscript identified 
and contrasted two sub-populations of myeloid cells that we identified in our analysis defined by 
HLA-DRintCD68intCD64intCD36+CD11b+ (Cluster 13) and HLA-DR+CD4+CD68+CD64+CD36-
CD11b- (Cluster 18). Visualization by high-dimensional box plot of these two populations revealed 
statistically significant differences (Mann-Whitney) in the six markers mentioned (Figure 1D). 
Next, we analyzed the lymphoid panel with a more conventional and faster hierarchical 
clustering approach. This approach yielded similar marker distributions via t-SNE heatmaps 
(Figure 4A). Furthermore, clustering of the data via hierarchical clustering (Figure 4B), 
demonstrated similar clusters of lymphoid cells (Figure 4C). Of note, we also identified the unique 
regulatory T cell population from the original manuscript defined as CD4+CD25+Foxp3+CTLA-
4+CD127- (Cluster 17) via our high-dimensional flow plot (Figure 4D).  
Finally, we wanted to employ a method within ExCYT to quickly and quantitatively assess 
co-associations among markers. We began by using a hard k-means clustering algorithm to lay 
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down 5000 clusters on the two-dimensional t-SNE data (Figure 4E). We then used the median 
expression of all the markers of all these clusters to create a heatmap from these clusters (Figure 
4F). Since these heatmaps cluster rows as well as columns that are similar, this method of 
abstracting the data by applying a fine mesh of clusters and then creating a heatmap allows us to 




Figure 3: Recapitulation of Myeloid Sub-Populations from Chevrier et al. (A) Token t-SNE 
heatmaps of myeloid panel (B) t-SNE plot of myeloid panel color coded by Network-Graph 
clustering algorithm (C) Heatmap of clusters identified by clustering solution on myeloid panel 
(D) Comparative high dimensional box plot comparing contrasting myeloid subpopulations 




Figure 4: Recapitulation of Lymphoid Sub-Populations from Chevrier et al. (A) Token t-SNE 
heatmaps of lymphoid panel (B) t-SNE plot of lymphoid panel color coded by hierarchical 
clustering algorithm (C) Heatmap of clusters identified by clustering solution on lymphoid panel 
(D) High dimensional flow plot of identified regulatory T cell population (Cluster 17) in original 
manuscript (E) Clustering solution of 5000 cluster hard k-means analysis on t-SNE data (F) 







Here we present ExCYT, a novel graphical user interface running MATLAB-based algorithms to 
streamline analysis of high-dimensional cytometry data, allowing individuals with no background 
in programming to implement the latest in high-dimensional data analysis algorithms. The 
availability of this software to the broader scientific community will allow scientists to explore 
their flow cytometry data in an intuitive and straightforward workflow. Through conducting t-SNE 
dimensionality reduction, applying a clustering method, being able to sort/filter through these 
clusters quickly, and make flexible, customizable heatmaps and high-dimensional flow/box plots, 
scientists will be able to not only understand the uniquely defined subpopulations in their samples 
but will be able to create visualizations that are intuitive and easily understood by their colleagues.  
While the program is flexible in handling a variety of data types (conventional flow 
cytometry vs mass cytometry), there are a few considerations for optimal utility of the program. 
The first of these is regarding the data quality, specifically of flow cytometry data. Proper 
compensation and resolution of overlapping emission spectra is of paramount importance. Poorly 
compensated data can inadvertently lead to false co-associations of markers and formation of 
clusters that are not of true biological significance. Therefore, it is highly advisable that the input 
data is of sound quality before proceeding with the t-SNE analysis and further downstream 
analysis. Furthermore, use of the automatic compensation algorithm implemented in ExCYT 
requires clear single stains for all channels in order to accurately calculate the compensation 
parameters.  
Another important consideration for use of ExCYT is when concatenating multiple FCS 
files into one analysis (as demonstrated in this manuscript), they must be comparable across all 
channels. First, this means that the same panel needs to be used across all samples and that there 
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is no drift between samples across all channels. For example, if one were to read two samples on 
separate days and stained CD8 in FITC on both days but the voltage of the cytometer was set 
differently on one day resulting in a slightly shifted CD8 population, one could generate false 
clusters in the downstream analysis, as this shift was generated as a function of instrument variation 
and not due to biological significance. While future versions of ExCYT may be able to normalize 
samples to their single stains, at this point, careful consideration must be made that FCS files can 
be compared to each other before importing them into ExCYT.  
Finally, the process of clustering is not one that is absolute/rigid. Different clustering 
algorithms and parameters can generate different clustering solutions. Whether the solution of the 
algorithm is appropriate is for the user to determine by synthesizing their understanding of the 
biology with the clustering solution. For example, when understanding the immune environment 
of tumors, one may be interested in macroscopic clusters (i.e., T cells vs B cells vs Myeloid cells) 
while another may be interested in subpopulations of macroscopic clusters. The resolution of the 
clusters is determined by the user and therefore, no single clustering solution is ‘correct.’ This is 
one of the main advantages of using the high dimensional flow plots available in ExCYT. The 
ability to visualize the distribution of a given cluster across all channels can help the user determine 
whether they have clustered in not only a biologically relevant way but in a way that is relevant to 
the scientific question being asked in the experiment. While our goal is to provide a plethora of 
methods used in the literature to cluster high-dimensional flow cytometry data while providing 
additional methods of clustering, we recommend using methods such as k-means and DBSCAN 
to explore the data via quickly iterating on cluster number and size and move towards network-
graph and gaussian-mixed model approaches for more robust but more time-consuming 
approaches. 
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Given these considerations, ExCYT is still a highly flexible and valuable tool for exploring 
high dimensional cytometry data, and offers unique/differentiating features than other available 
packages available to conduct this type of analysis (Table 2). First, ExCYT differentiates itself 
over most flow cytometry analysis approaches utilizing dimensionality reduction and clustering 
algorithms by its ability to be used without any scripting/programming knowledge. Additionally, 
by aggregating many clustering algorithms cited throughout the literature, we believe we provide 
the most options for clustering data. Finally, our unique feature of cluster filtration and sorting 
along with display via novel high dimensional flow plots, allows users to explore the 
characteristics of their clusters quickly and efficiently, making the process of ‘discovering’ rare 





Table 2: Overview of Software-assisted Flow Cytometry Analysis Solutions  
  
Name of Software/Package ExCYT CYT FCS Express flowCore openCyto FlowMeans
Program Type Matlab Matlab Stand-Alone Application R R R
Price to User Free Free $1,000 Free Free Free
Graphical User Interface Yes Yes Yes No No No






Multiple Network-Graph Based 
Methods
GMM - EM




Single Network-Graph Based 
Method (Phenograph)
K-Means none
automation of manual gating 
workflow
K-Means
Ability to Sort/Filter Clusters Yes No No No No No
High Dimensional Flow Plots Yes No No No No No
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VI. Convolving Pre-Trained Convolutional Neural Networks at Various Magnifications to 
Extract Diagnostic Features for Digital Pathology 
Abstract 
 
Deep learning is an area of artificial intelligence that has received much attention in the past few 
years due to both an increase in computational power with the increased use of graphics 
processing units (GPU’s) for computational analyses and the performance of these class of 
algorithms on visual recognition tasks. They have found utility in applications ranging from 
image search to facial recognition for security and social media purposes. Their continued success 
has propelled their use across many new domains including the medical field, in areas of 
radiology and pathology in particular, as these fields are thought to be driven by visual 
recognition tasks. In this paper, we present an application of deep learning, termed ‘transfer 
learning’, using ResNet50, a pre-trained convolutional neural network (CNN) to act as a ‘feature-
detector’ at various magnifications to identify low and high level features in digital pathology 
images of various breast lesions for the purpose of classifying them correctly into the labels of 
normal, benign, in-situ, or invasive carcinoma as provided in the ICIAR 2018 Breast Cancer 




While artificial intelligence and machine learning have revolutionized many scientific fields, 
perhaps no other method has had the widespread adoption and practical use as much as deep 
artificial neural networks, or otherwise known as ‘deep learning.’ Of note, deep learning has had 
a profound impact on tasks associated with visual recognition, bringing about technologies capable 
of object classification and image recognition66. With the reduction to practice in many fields such 
as social media and communication technologies, there has been a recent advent to bring deep 
learning into the medical field. One of the initial applications of deep learning in the medical field 
was by a group at Stanford led by Sebastian Thrun who used transfer learning to classify skin 
lesions into benign, non-neoplastic, and malignant subtypes10. This proof of concept has led an 
initiative to bring deep learning into other visual recognition tasks in the medical field including 
radiology and digital pathology103,104. Not only have these approaches been shown effective in 
providing diagnostic power, comparable to medical professionals, but they also have shown 
promise to help learn features possibly missed by humans that can help differentiate various 
pathologies105.  
Despite the promise of deep learning for applications in the medical field, due to the 
novelty of these applications, there exists little labeled data for supervised machine learning. 
However, prior work in the fields of deep learning has shown the power of a technique called 
‘transfer learning,’ the idea being that pre-existing designed architectures (i.e. ResNet50, 
AlexNet, VGG16) that have been trained on possibly millions of images for over 1000 image 
classes can serve as ‘professional feature detectors’ for new visual recognition tasks where data 
may not be as abundant. While it may seem far fetched that a convolutional neural network (CNN) 
trained to recognize dogs and cats could recognize relevant features in medical imaging, Sebastian 
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Thrun and his group demonstrated this exact concept could be utilized, generating results even 
better than when training a CNN de-novo to diagnose skin lesions10. In this manuscript, we 
propose a method by which one can use ResNet50, a pre-trained CNN, as a feature detector for 
classification of normal, benign, in-situ, and invasive breast carcinoma. We propose a method by 
which convolving this pre-trained net at various magnifications of labeled pathology image tiles 
can serve to detect low and high-level features in digital pathology that can be ultimately used for 
the task of lesion classification.   
Methodology  
Data-Set  
For the task of classifying various types of breast pathology images, we were provided a set of 
400 images (100 per class) of normal, benign, in-situ, and invasive breast carcinoma. 
Additionally, with a set of 20 whole slide images (WSI), we were able to extract an additional 
648 image tiles of invasive, in-situ, and normal breast tissue with the assistance of a pathologist. 
For the remaining of the manuscript, we will refer to the first set as Data Set A and the latter set 
as Data Set B.   
Color Normalization & Image Augmentation  
In order to account for the variation in color we conducted an image color augmentation routine 
in which we characterized each of the tiles provided in the first part of this competition using the 
Reinhard method106 , which transforms the RGB color image to the CIELAB colorspace. We then 
converted the CIELAB projections into the HSV colorspace and then selected 5 representative 
tiles from the spectrums observed at the 10th, 25th, 50th, 75th, and 90th percentiles for both hue 
(H) and value (V). We then made 10 color transformation for each input image to the 10 
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representative tiles identified above using the Reinhard color transfer method, thus constituting 
our image color augmentation approach.  
Neural Network Architecture  
In initial tests using ResNet50 as a pre-trained feature extractor for the pathology image tiles, we 
noticed a lack of resolution and detail as many of these pre-trained CNN’s take fairly small images 
(244 x 244 pixels). In order to maintain resolution of important features of the pathology while 
also approaching the problem with the inspiration of how a pathologist examines slides, we 
decided to convolve ResNet50 at two magnifications (100x100 μm, 400x400 μm) with a stride 
length that was half of the kernel length (Figure 1). The output of each convolution was a [n-
windows, 2048] feature map on which we took the maximum value for each ResNet50 feature. 
This feature extraction was done with the Keras implementation of ResNet50 where the top layer 
was not included and an average pooling was done to obtain the 2048 features for each window. 
At the end of this step, each magnification has a 2048-element vector that reflects the presence 
of a given ResNet50 feature at a given magnification of the pathology image tile. At this point, 
we concatenate the 2048-element vector from both magnifications used to create a [2,2048] tensor 
that is then flattened and used as an input to a trainable fully-connected layer of 512 neurons, 
trained with a 20% dropout rate, followed by the final multi-class classification layer for the 4 
output classes (normal, benign, in-situ, and invasive) with a softmax activation layer. 





In order to train the fully-connected layers of the CNN, we split up our data-set into training, 
validation, and test sets. We used an 90/5/ split across these respective sets, 5 batches of images 
per epoch, with 100-fold cross-validation to assess performance via receiver operating 
characteristic (ROC) curves, confusion matrices to examine individual class accuracy, and 
measured overall accuracy of the algorithm. We implemented an early stopping approach where 
after a minimum of 100 epochs, we stopped training when the validation loss did not decrease by 
2% in the previous 50 epochs or the validation accuracy did not increase by 5% in the previous 
200 epochs. After 100-fold training, we averaged the weights of each training session to arrive at 




We wanted to assess the ability of neural network to learn the underlying pathologies from two 
separate sources of pathology images so we conducted a series of experiments where we ran 100x 
Monte Carlo cross validation with a train/test split of 90/10 percent. We then varied the data 
available for training, as shown in the figures below while assessing performance on the original 
Data Set A. We varied the training data based on combination of Data Sets A & B (as described 
in the methods above) and the use of the image color augmentation approach we implemented, 
which is described in the methods.  
  
  
Figure 2. Train on Data Set A, Test on Data Set A - No Image Color Augmentation  
With these 400 images, we obtained an overall accuracy of 84.3% across all four classes.  
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Figure 3. Train on Data Set A, Test on Data Set A - Image Color Augmentation  
When introducing augmented images into the training set, we saw an increase in overall accuracy 
up to 86.2%.  
  
Figure 4. Train on Data Set A & Data Set B, Test on Data Set A - No Image Color 
Augmentation  
When introducing a second data set into our training set, we saw an increase in overall accuracy 




Figure 5. Train on Data Set A & Data Set B, Test on Data Set A - With Image Color 
Augmentation  
When introducing color augmentation into the training of both data sets A and B, we observed an 
overall accuracy of 84.4%.  
In comparing figure 2 and 3, we observed that the introduction of our image color augmentation 
approach increased the accuracy in the validation data by a small factor of approximately 2%. In 
comparing figure 2 and 4, we also noted a small increase of approximately 1 % in performance 
when including the additional images (Data Set B) derived from the WSI data also provided in 
the ICIAR 2018 BACH challenge. Somewhat surprisingly, when comparing figure 2 to figure 5, 
we did not observe an increase in performance with image color augmentation applied to the 
training set that include data sets A & B.   
Conclusion  
Here we present a method of convolving ResNet50, a pre-trained convolutional neural network, 
across pathology image tiles at various magnifications to identify low and high-level features that 
can be later fed into trainable fully-connected layers for the purpose of accurately classifying 
various types of breast lesions. While we were able to get a respectable accuracy through this 
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method, we believe we were still making mistakes in classification that would be considered 
obvious to a pathologist. While we never explored the idea of re-training or fine-tuning the 
weights within ResNet50, we hypothesize this approach may be able to push the performance 
further beyond what we have been able to show here.   
Furthermore, when examining the clinical utility of such an algorithm, we felt future 
directions should focus differentiating cancer from non-cancer primarily as algorithms such as 
this one will initially have value in the capacity of being screening tests. We believe in order to 
make this a viable, clinically useful algorithm, future efforts should be placed in ruling out normal 
images with a high degree of confidence, regardless of the false positive rate for cancer detection 







In this work, we demonstrate the power of artificial intelligence to have tremendous 
potential for generating insights in a variety of datasets within the field of cancer immunology. 
Through the development of ImmunoMap and DeepTCR, we exhibit how two types of machine 
learning approaches can provide structural insights into T-cell repertoire. Ultimately, tools such as 
these will be useful to understanding the antigenic-composition of the adaptive immune response 
in cancer. AI-MHC attempts to understand the other side of the immune synapse in attempting to 
better predict Class I and Class II antigens for the purpose of improved neoantigen prediction. 
Finally, we demonstrate how conventional high-dimensional analytics can be packaged into useful 
tools for the broader community through the development of ExCYT, a software package for high-
dimensional cytometry analysis. I believe the concepts developed within this doctoral work will 
be foundational for a comprehensive assessment of all the players that are involved in the immune 
system-cancer interaction that will lead to breakthroughs in understanding that advance therapy 
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Supplementary Figure 1. In order to set thresholds for motif detection, two variables were optimized on 
a Naïve Adult B6 CD8 Repertoire (taken from Adaptive Biotechnologies ImmunoSeq Sample Data). Motif 
detection was completed across a range of phylogenetic distances and frequency thresholds and number 
of motifs detected was monitored. Since our analysis was looking for dominant motifs above what is 
present in an unexpanded population, we chose a frequency threshold of 0.03 and Phylogenetic Distance 

















Supplementary Figure 2. A) FACS analysis of antigen-specific CD8 T cells on D7 in Naïve and Tumor-bearing 
lymphoid organs. B) ICS staining of antigen-specific CD8 T Cells confirming specificity and functionality. C) 
Comparison of Dimer+ and TNF+ CD8. D) Antigen-specific CD8 T cells staining from splenic CD8 T cells 
directly ex vivo compared to unloaded Kb-Ig staining. N = 3, Statistical 2-tailed T-test. 
 
 


































































































































































































































































































Supplementary Figure 5. In order to determine number of tumor-infiltrating lymphocytes that were 
sequenced for each patient, Adaptive reported amount of total DNA in nanograms that underwent 
sequencing and based on the assumption of 6.5pgDNA per cell, we were able to calculate the number of 
total cells that underwent sequencing. Furthermore, Adaptive calculated a %TIL metric based on number 
of non-recombined to recombined sequence reads. With this information, we were able to deduce the 











B)   
for i=1:size(DistanceMatrix3,1); 
        for j=1:size(DistanceMatrix3,2); 
            if i==j 
                if Reads(i)==1 
                    ScorePreOut(i,j)=0; 
                else 
                    ScorePreOut(i,j)=DistanceMatrix3(i,j)*combntns(Reads(i),2); 
                end 
            else 
                ScorePreOut(i,j)=DistanceMatrix3(i,j)*Reads(i)*Reads(j); 
            end 
        end 
    end 
 
   TCRDiversityScore=1-(sum(sum(ScorePreOut))/combntns(sum(Reads),2)); 
 
 
Supplementary Figure 6. Calculation of TCR Diversity Score. A) Initially, all pair-wise distances are 
calculated with sequence distance based on global alignment scores. Sequence distance is then converted 
to a mapped sequence distance with values between 0 and 1. This Mapped Sequence Distance is defined 
as 0 being infinite sequence difference and 1 being identify. B) The distance matrix that is calculated is 
then weighted by the number of reads. The purpose of this step is to determine the average distance 
between every cell in the analysis. The piece of code iterates through the distance matrix calculated in A. 
If i==j (meaning that we are examining the same sequence against itself) and there exists only 1 read of 
that sequence, the new matrix calculation is 0, meaning there is no need to calculate a distance between 
a read and itself. If there is more than 1 read, then the new matrix entity calculation is the distance of the 
sequence and itself multiplied by the total number of all possible combinations of those reads. For 
example, if there are 10 reads of a given sequence, this new matrix entity is calculated as 1 (sequence 
distance) * 45 (all possible combinations of 10 reads). In all other cases, where the two sequences are 
different, the new matrix entity is calculated as the distance between those two sequences multiplied by 
the number of reads of the first sequence multiplied by the reads of the second sequence. Finally, this 
new matrix is summed and divided by the number of possible combinations of all reads. This number is 
then subtracted by 1 to give the final Mapped Sequence Distance where 0 represents identity and 1 
represents infinite difference. 
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Supplementary Figure 7. Duplicates of Murine Experiments. Corresponding duplicate figures to Figures 










Supplementary Figure 8. ImmunoMap Graphical User Interface & Instructions for Use. 
1) User selects files for analysis by pressing the ‘Select Files’ button and importing tsv files of TCRSeq 
Data exported by Adaptive Biotechnologies. If one has a different source of TCRSeq, one can 
submit a tsv file with the first column being nucleotide sequences, the second column being amino 
acid sequence, and the third column being number of counts.  
2) After importing the files, one can set a variety of ImmunoMap parameters including how much of 
the file to use, structural homology thresholds, cluster frequency thresholds as well as parameters 
such as the scoring matrix used and the gap penalty.  
3) After parameters have been set, one highlights the files under the ‘Select Files’ button they want 
to analyze at once. At this point, the user can press ‘Run Immunomap’ and get a table of all 
relevant ImmunoMap metrics for their respective files. For each file, they can view the multiple 
alignments of their dominant motifs by selecting the file and the motif in the window to the right 
and pressing ‘Visualize Dominant Motifs.’ Finally, one can save a csv file with all the summarized 
ImmunoMap metrics by pressing the ‘Save Table to CSV’ button. This file can be opened by 
Microsoft Excel using a comma as the delimiter.  
4) If one desire to compare multiple files by visualizing them by the Weighted Repertoire 
Dendrograms, they can highlight the desired files for visualization in the window beneath the 
‘Select Files’ button and press ‘View Weighted Repertoire Dendrogram.’  
5) Finally, if one desires to compare two repertoires by seeing the percent of structural overlap as 
well shared dominant motifs, one should select the two files they want to compare in the drop 





Supplementary Figure 9. TCRSeq File Structure. Following processing by Adaptive 
Biotechnologies, we received data in this general format. The first column is the nucleotide level 
sequence of the T-cell clones. The second column is translated from the first column. The counts 
and frequency columns are used to determine the abundance of a given clone. During processing 
of the data, we collapse all nucleotide clones that share the same amino acid sequence and sum the 




Dataset Host Pathology Description 
Glanville_2017 Human None T-cells were tetramer sorted for 7 Class I specificities.  
Sidhom_2017  Murine None 
CD8 T-cells were stimulated and expanded against SIY 
and TRP2 antigens before being sorted and 
sequenced. 
Rudqvist_2017 Murine Cancer 
Tumor-infiltrating lymphocytes were collected from 
mice who either received no treatment, radiation 
therapy, anti-CTLA4 (9H10), or combo therapy. 
 
 
Supplementary Figure 10. Dataset Descriptions. DeepTCR was piloted on three sources of data 






Supplementary Figure 11. Quantitative TCRSeq Metrics. (a) Distribution of clonalities across 
all samples used in this manuscript. We note the majority of samples have a high clonality. (b) 





Supplementary Figure 12. GAN Losses. Prototypical discriminator and generator losses during 





Supplementary Figure 13. VAE vs. GAN Clusters. We used the Sidhom_2017 dataset to do 
hierarchical clustering on the latent feature space for both the VAE and the GAN to note 
differences in the clustering solutions. Since the objective function of the VAE is to reconstruct 
the sequence, we note the latent space contains knowledge about the length of the sequences and 
thus, clusters use sequences of similar length. In contrast, since the GAN’s objective functions do 
not rely on reconstruction of the sequences, the clusters use sequences of variable length. (a) 
Hierarchical clustering was performed on SIY-specific sequences, creating 100 flat clusters 
following dimensionality reduction via VAE or GAN. The distribution of the variance of sequence 




Supplementary Figure 14: Rudqvist_2017 Sequence Features. A subset of sequences is shown 
by their learned unsupervised features from either the variational autoencoder or the generative 



































Supplementary Table 1. 
Supertype Classification of Class 
I Alleles as determined by Sidney 



























































































Supplementary Table 2. All Class I 





























































































Supplementary Table 3. Detailed assessment IEDB Class I ic50 benchmarks.  Shown are AI-MHC along with 11 
provided algorithms on the website. AUC values are reported for a given benchmark (identified by IEDB 
reference, Allele Name, Peptide Length, Peptide Count, and Measurement Type). Bold indicates the algorithm 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 4. All Class II 












































































































Supplementary Table 5. Detailed assessment IEDB Class II ic50 benchmarks.  Shown are AI-MHC along with 
11 provided algorithms on the website. AUC values are reported for a given benchmark (identified by IEDB 
reference, Allele Name, Peptide Length, Peptide Count, and Measurement Type). Bold indicates the algorithm 
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